

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No.

P01899US2

First Inventor or Application Identifier

Huda Y. Zoghbi

Title

Compositions and Methods for the Therapeutic Use an Atonal-Associated Sequence for Deafness, Osteoarthritis and Abnormal Cell Proliferation

Express Mail Label No.

EK102714210US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification (preferred arrangement set forth below) **Total Pages** 135
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Reference of Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) **Total Sheets** 14
4. ☐ Oath or Declaration **Total Pages**
- ☐ Newly executed (original or copy)
 - ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 17 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 C.F.R. §§
1.63(d)(2) and 1.33 (b)
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or
disclosure is disclosed under Box 4b, is considered to be a part of the
disclosure of the accompanying application and is hereby incorporated by
reference therein

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. § 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity Statement(s) (PTO/SB/09-12) ☐ Statement filed in prior
application, Status is proper and
desired
15. ☐ Certified Copy of Priority Document(s)
16. ☒ Other: Priority claimed: 60/137,060 filed 6/1/99 and
60/176,993 filed 1/19/00

*** NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY
FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF
ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)**

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

- ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.
- Prior application information: Examiner: Group / Art Unit.

18. CORRESPONDENCE ADDRESS

- ☐ Customer Number or bar code label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	Melissa L. Sistrunk				
Address	Fulbright & Jaworski L.L.P., 1301 McKinney, Suite 5100				
City	Houston	State	TX	ZIP Code	77010-3095
Country		Telephone	(713) 651-3735	Fax	(713) 651-5246

Name (Print/Type)	Melissa L. Sistrunk	Registration No. (Attorney/Agent)	45,579
Signature	Melissa L. Sistrunk	Date	6/1/2000

[illegible]

The United States Government may have certain rights in the invention.

5

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	

10

14

20

subclass of transcription factors, belonging to the basic helix-loop-helix (bHLH) family of proteins, is expressed early on when the decision to proliferate or differentiate is made. This function is a particularly crucial one as mutations in these genes early in development can wipe out entire neural structures.

5 In *Drosophila*, the gene *atonal* (*ato*), which is homologous to *Math1*, *Math2*, *Hath1* and *Hath2*, encodes a bHLH protein essential for the development of chordotonal organs (sensory organs found in the body wall, joints and antenna that function in proprioception, balance and audition) (Eberl, 1999; McIver, 1985; van Staaden and Römer, 1998). CHOs populate the peripheral nervous system (PNS) in the body wall and
10 joints (thorax, abdomen, sternum, wings, legs) and antennae (Moulins, 1976), providing the fly with sensory information much as touch and mechanoreceptors do in vertebrates (McIver, 1985; Moulins, 1976). Boyan (Boyan, 1993) proposed that, in the course of evolution, different CHOs became specialized for hearing in different insects. This hypothesis was recently confirmed by van Staaden and Römer (1998). In *Drosophila*,
15 CHOs in the Johnston organ, located in the second antennal segment, function in near field hearing (Dreller and Kirschner, 1993; Eberl, 1999) and negative geotaxis.

During development *ato* is expressed in a cluster of progenitor cells from which the CHO founder cells are selected (Jarman et al., 1993). It likely functions by regulating the expression of genes necessary for the specification and development of the CHO
20 lineage; as it encodes a basic helix-loop-helix protein (bHLH) that dimerizes with the Daughterless protein and binds to E-box sequences, thereby activating genes (Jarman et al., 1993). CHO specificity is encoded by the *ato* basic domain, which is required for DNA binding in bHLH proteins (Chien et al., 1996; Davis et al., 1990; Jarman and

Ahmed, 1998; Vaessin et al., 1990). *ato* is both necessary and sufficient for the generation of CHOs in the fly: loss of *ato* function leads to the loss of CHOs, while ectopic *ato* expression causes ectopic CHO formation (Jarman et al., 1993). Adult flies that lack *atonal* function are uncoordinated, do not fly, and are deficient in hearing.

- 5 Overexpression of the fly *atonal* gene can generate new chordotonal neurons, indicating that *atonal* is both essential and sufficient for the development of this neuronal population.

In vertebrates, during myogenesis and neurogenesis, cell fate specification requires basic helix-loop-helix (bHLH) transcription factors. *Math1* (for mouse a*tonal* homolog-1) is such a factor, and is expressed in the hindbrain, dorsal spinal cord, external germinal layer of the cerebellum, gut, joints, ear and Merkel cells of the skin (which function as mechanoreceptors) (Akazawa et al., 1995; Ben-Arie et al., 1996; Ben-Arie et al., 1997). Mice heterozygous for a targeted deletion of *Math1* (*Math1*^{+/-}) are viable and appear normal, but *Math1* null mice (*Math1*^{-/-}) die shortly after birth and lack cerebellar granule neurons.

10
15

Math1 is one of *ato*'s closest known homologs, with 82% amino acid similarity in the bHLH domain and 100% conservation of the basic domain that determines target recognition specificity (Ben-Arie et al., 1996; Chien et al., 1996). *Math1* is transiently expressed in the CNS starting at embryonic day 9 (E9) in the dorsal portion of the neural tube. *Math1* is also expressed in the rhombic lip of the fourth ventricle of the brain, where cerebellar granule cell precursors are born at E13-15 (Alder et al., 1996). Upon proliferation and differentiation, these progenitor cells migrate to form the external granule layer (EGL) of the cerebellar primordia (Hatten and Heintz, 1995). Proliferating

20

EGL cells continue to express *Math1* during the first three postnatal weeks, until shortly before they migrate to their final adult destination to generate the internal granule layer (IGL) of the cerebellum (Akazawa et al., 1995; Ben-Arie et al., 1996). Another group of cells, a small population of neuronal precursors in the dorsal spinal cord, expresses *Math1* during E10-E14 (Akazawa et al., 1995; Ben-Arie et al., 1996). These precursor cells also express the LIM homeodomain proteins (LH2A and LH2B), markers of the D1 class of commissural interneurons (Lee et al., 1998). Helms and Johnson (1998) reported that *lacZ* expression under the control of *Math1* regulatory elements reproduced *Math1* expression patterns in the developing cerebellum and spinal cord, and demonstrated that *Math1* is expressed in precursors that give rise to a subpopulation of dorsal commissural interneurons.

To determine the in vivo function of *Math1*, the inventors generated mice (*Math1*^{-/-}) lacking the MATH1 protein. This null mutation causes major cerebellar abnormalities: lack of granule cell proliferation and migration from the rhombic lip at E14.5, and absence of the entire EGL at birth (Ben-Arie et al., 1997). It is not clear whether the agenesis of cerebellar granule neurons is due to failure of progenitor specification or the cells' inability to proliferate and/or differentiate. Neonates cannot breathe and die shortly after birth, but there are no gross defects in any cranial nerves or brain stem nuclei that could explain respiratory failure.

The fact that *Math1* is expressed in the inner ear suggests that *Math1* expression is necessary for the development of auditory or balance organs. The inner ear initially forms as a thickening of the ectoderm, termed the otic placode, between rhombomeres 5 and 6 in the hindbrain. The otic placode gives rise to neurons of the VIIIth cranial

nerve and invaginates to become the otocyst, from which the inner ear will develop. The mature mammalian inner ear comprises one auditory organ, the cochlea, and five vestibular organs: the utricle, the saccule, and three semicircular canals. The sensory epithelia of these organs consist of mechanoreceptive hair cells, supporting cells and nerve endings. Hair cells serve as mechanoreceptors for transducing sound waves and head motion into auditory and positional information. Hair cells and supporting cells both arise from a common progenitor cell and proliferate and differentiate within the sensory epithelia, with peak mitoses between embryonic day 13 and 18 (E13-18) in mice. Although several genes have been implicated in the development of the inner ear, such as *int2* (Mansour et al., 1993; *pax2* (Torres et al., 1996; and *Hmx3* (Wang et al., 1998). None have been shown to be required for the genesis of hair cell specifically.

Damage to hair cells is a common cause of deafness and vestibular dysfunction, which are themselves prevalent diseases. Over 28 million Americans have impaired hearing; vestibular disorders affect about one-quarter of the general population, and half of our elderly. The delicate hair cells are vulnerable to disease, aging, and environmental trauma (i.e., antibiotics, toxins, persistent loud noise). Once these cells are destroyed, they cannot regenerate in mammals. Therefore, a need exists to address the problems of patients with congenital, chronic or acquired degenerative hearing impairment and loss or balance problems, and to provide compositions, methods and reagents for use in treating hearing loss and vestibular function.

In support of the teaching of the present invention, others have demonstrated that *Math1*, upon overexpression, induces significant production of extra hair cells in postnatal rat inner ears (Zheng and Gao, 2000). Briefly, although fate determination is

usually completed by birth for mammalian cochlear hair cells, overexpression of *Math1* in postnatal rat cochlear explant cultures results in additional ear hair cells which derive from columnar epithelial cells located outside the sensory epithelium in the greater epithelial ridge. Furthermore, conversion of postnatal utricular supporting cells into hair cells is facilitated by *Math1* expression. The ability of *Math1* to permit production of hair cells in the ear is strong evidence in support of the claimed invention.

SUMMARY OF THE INVENTION

In one embodiment of the present invention there is an animal having a heterologous nucleic acid sequence replacing an allele of an *atonal*-associated nucleic acid sequence under conditions wherein said heterologous sequence inactivates said allele. In a preferred embodiment said heterologous sequence is expressed under control of an *atonal*-associated regulatory sequence. In a specific embodiment both *atonal*-associated alleles are replaced. In an additional specific embodiment both *atonal*-associated alleles are replaced with nonidentical heterologous nucleic acid sequences. In an additional embodiment said animal has a detectable condition wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, imbalance, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation of medulloblastoma. In another embodiment of the present invention said heterologous nucleic acid sequence is a reporter sequence selected from the group consisting of β -galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase, β -glucuronidase and chloramphenicol transferase (CAT). In

another specific embodiment said reporter sequence regulatable or is expressed in brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear sensory epithelia and brain stem nuclei. In additional specific embodiments said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under control of a regulatable promoter sequence or a tissue-specific promoter sequence wherein said tissue is selected from the group consisting of brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear sensory epithelia and brain stem nuclei. In additional embodiments said animal is a mouse, *Drosophila*, zebrafish, frog, rat, hamster or guinea pig.

10 In another embodiment of the present invention is a method for screening for a compound in an animal, wherein said compound affects expression of an *atonal*-associated nucleic acid sequence comprising delivering said compound to said animal wherein said animal has at least one allele of an *atonal*-associated nucleic acid sequence inactivated by insertion of a heterologous nucleic acid sequence wherein said
15 heterologous nucleic acid sequence is under control of an *atonal*-associated regulatory sequence, and monitoring for a change in said expression of said *atonal*-associated nucleic acid sequence. In specific embodiments said compound upregulates or downregulates said expression of an *atonal*-associated nucleic acid sequence. In additional embodiments said animal is a mouse or *Drosophila*. In a specific embodiment
20 the heterologous nucleic acid sequence is a reporter sequence. In an additional specific embodiment the heterologous nucleic acid sequence is selected from the group consisting of β -galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP),

neomycin, kanamycin, luciferase, β -glucuronidase and chloramphenicol transferase (CAT).

Another embodiment of the present invention is a compound which affects expression of an *atonal*-associated nucleic acid sequence. In specific embodiments said
5 compound upregulates or downregulates expression of an *atonal*-associated nucleic acid sequence. In a specific embodiment said compound affects a detectable condition in an animal wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and
10 formation of medulloblastoma.

Another embodiment of the present invention is a method for screening for a compound in an animal, wherein said compound affects a detectable condition in said animal, comprising delivering said compound to said animal wherein at least one allele of an *atonal*-associated nucleic acid sequence in said animal is inactivated by insertion
15 of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under the control of an *atonal*-associated regulatory sequence, and monitoring said animal for a change in the detectable condition. In a specific embodiment said detectable condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease,
20 osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation of medulloblastoma. In another embodiment said delivery of said compound affects expression of said heterologous nucleic acid sequence. In specific embodiments said expression of said heterologous nucleic acid sequence is upregulated or downregulated.

In additional specific embodiments said animal is a mouse, *Drosophila*, zebrafish, frog, rat, hamster or guinea pig.

Another embodiment of the present invention is a compound wherein said compound affects said detectable condition. In specific embodiments said compound affects expression of a heterologous nucleic acid sequence. In additional specific
5 embodiments said compound upregulates or downregulates expression of a heterologous nucleic acid sequence.

In other embodiments of the present invention are methods of treating an animal, including a human, for cerebellar granule neuron deficiencies, for promoting
10 mechanoreceptive cell growth, for generating hair cells, for treating hearing impairment or an imbalance disorder, for treating a joint disease, for treating for an abnormal proliferation of cells, and for treating for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence. Said methods include administering a therapeutically effective amount of an *atonal*-associated nucleic acid or
15 amino acid sequence. In specific embodiments said administration is by a vector selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated vector, a plasmid, or any other nucleic acid based vector, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof of said vectors. In a specific embodiment said vector is a non-viral vector or a viral vector. In another specific
20 embodiment said vector is a cell. In a preferred embodiment said vector is an adenovirus vector comprising a cytomegalovirus IE promoter sequence and a SV40 early polyadenylation signal sequence. In another specific embodiment said cell is a human cell. In an additional specific embodiment said joint disease is osteoarthritis. In a

specific embodiment said *atonal*-associated nucleic acid or amino acid sequence is *Hath1* or *Math1*. In another specific embodiment the cell contains an alteration in an *atonal*-associated nucleic acid or amino acid sequence. In an additional specific embodiment said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58. In an additional specific embodiment the nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58.

In another embodiment of the present invention is a method for treating an animal for an abnormal proliferation of cells comprising altering *atonal*-associated nucleic acid or amino acid sequence levels in a cell. In a specific embodiment said alteration is reduction or said nucleic acid or amino acid sequence contains an alteration.

In another embodiment of the present invention is a composition comprising an *atonal*-associated amino acid sequence or nucleic acid sequence in combination with a delivery vehicle wherein said vehicle delivers a therapeutically effective amount of an *atonal*-associated nucleic acid sequence or amino acid sequence into a cell. In specific embodiments said vehicle is the receptor-binding domain of a bacterial toxin or any fusion molecule or is a protein transduction domain. In a specific embodiment said protein transduction domain is from the HIV TAT peptide. In a specific embodiment said *atonal*-associated amino acid sequence or nucleic acid sequence is *Hath1* or *Math1*.

In another embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific

embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or

alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism
5 comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

10 In another embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic
15 acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises a
20 defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises a defect in an *atonal*-

associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific
5 embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the
10 present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an *atonal*-associated
15 nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises defect in a nucleic acid sequence
20 which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an amino acid

sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In a specific embodiment said cancer is medulloblastoma.

Other and further objects, features and advantages would be apparent and eventually more readily understood by reading the following specification and by reference to the company drawing forming a part thereof, or any examples of the presently preferred embodiments of the invention are given for the purpose of the disclosure.

DESCRIPTION OF THE DRAWINGS

Figure 1A and 1B demonstrate that the inner ear β -Gal staining (blue) of *Math1* heterozygous embryos as described hereinabove. Figure 1A shows the otic vesicle (OV) at E12.5 and Figure 1B the inner ear at E14.5 of *Math1*^{+/ β -Gal} embryos. Sensory epithelia stained positively in the cochlea (C), saccule (S), utricle (U), and semicircular canal ampullae (SCA). A schematic diagram of the inner ear is depicted alongside the staining for reference, blue indicates location of the sensory epithelia. The original magnifications of the images taken under the microscope were x100 For Figure 1A and x50 for Figure 1B.

Figures 2A through 2F are scanning electron micrographs of E18.5 inner ear sensory epithelia in wild-type and *Math1* ^{β -Gal/ β -Gal} mice. Wild-type mice epithelia are shown in Figures 2A, 2C, and 2E and null mouse epithelia in Figures 2B, 2D, and 2F. The organ of Corti of the cochlea are shown and indicated in Figures 2A and 2B. In the

wild-type mouse there are three rows of outer hair cells (1, 2, 3), one row of inner hair cells (I), all with hair bundles (HB). The tectorial membrane (TM), an accessory structure of the cochlea, can be observed at the bottom. Above the sensory epithelium are squamous cells (SQ) with rudimentary kinocilia (RK). In null mice (Figure 2B), there are only squamous cells. Crista ampullaries of a vertical semicircular canal are depicted in Figures 2C and 2D. The null mouse crista is similar to the wild-type in overall shape, including the septum (eminentia) cruciatum (EC), but is smaller. The macula of the utricle is the focus of Figure 2E and 2F. Again, the macula of the null mouse is smaller than the wild-type. Scale bars are as follows: 10 μm in Figures 2A and 2B, 50 μm in Figures 2C and 2D, and 100 μm in Figures 2E and 2F.

Figures 3A through 3F are light micrographs of semi-thin transverse sections of inner ear sensory epithelia in wild-type mice (Figures 3A, 3C, and 3E) and *Math1* ^{β -Gal/ β -Gal} (Figures 3B, 3D, and 3F), all mice were observed at E18.5. As observed in the cochlea of wild-type mice, Figure 3A, three outer hair cells (1, 2, 3) and one inner (I) hair cell are present. Conversely, the null mouse cochlea (Figure 3B) has only squamous cells (SQ) in the same region. Hair cells (HC) and supporting cells (SC) are present in the wild-type crista ampullaris (Figure 3C) and utricular macula (Figure 3E), but only supporting cells are present in null mice (Figure 3D and 3F). The crista was cut obliquely, accounting for the multiple layers of hair cells in Figure 3C. The otolithic membrane (OM), an accessory structure of the utricle, is present in both wild-type mice (Figure 3E) and null mice (Figure 3F). Scale bars equal 100 μm in (Figures 3A and 3B); 50 μm in (Figures 3C and 3D); and 25 μm in (Figures 3E and 3F).

Figures 4A and 4B are transmission electron micrographs of E18.5 utricular macula in wild-type and *Math1* ^{β -Gal/ β -Gal} mice. Figure 4A shows that the hair cells (HC) and supporting cells (SC) are present in wild-type utricular macula. By contrast, only supporting cells are present in the null mouse (Figure 4B). Hair cells have hair bundles (HB) and supporting cells have microvilli (MV). Hair cells are less electron-dense and have more apical nuclei than supporting cells, but only the latter have secretory granules (SG). Some immature hair cells (IM) are evident in the wild-type, but not in the null mouse. The scale bar in all the figures equals 10 μ m.

Figures 5A through 5F show the Calretinin staining pattern of inner ear sensory epithelia. Sections through the utricle of E16.5 wild-type (Figures 5A and 5C) and *Math1* ^{β -Gal/ β -Gal} (Figure 5B and 5D) littermates were counterstained with propidium iodide (red) for confocal microscopy. Sections were cut through the crista ampullaris of E18.5 wild-type (Figure 5E) and *Math1* ^{β -Gal/ β -Gal} (Figure 5F) were counterstained with DAPI (blue) for immunofluorescent microscopy. The crista is cut at an oblique angle, which accounts for the multiple layers of hair cells in (Figure 5E). Immunostaining of Calretinin (green, arrows) is evident in hair cells of wild-type (Figures 5A, 5C, and 5E) but not null mice (Figures 5B, 5D, and 5F). Boxed areas in Figures 5A and 5B indicate the regions magnified in Figures 5C and 5D. Scale bar equals 100 μ m in (Figure 5A and 5B), 15 μ m in (Figures 5C and 5D) and an original magnification of x200 in (Figures 5E and 5F).

Figure 6A and 6B show the expression pattern of *Math1* in mouse articular cartilage using the *Math1*^{+/ β -Gal} heterozygote. Figure 6A shows the staining pattern of a P14 mouse forelimb and demonstrates expression in all joints. Figure 6B is a

magnification (20X) of an elbow joint from the same mouse that demonstrates that *Math1* is expressed exclusively in the non-ossified articular chondrocytes.

Figure 7A through 7C show replacement of *Math1* coding region by *lacZ* gene. Figure 7A, Top, has a map of the *Math1* genomic locus. The coding region is shown as a black box. The sites of the probes used to detect the wild-type and mutant alleles are shown as black bars. The targeting vector is in the middle with the sites for homologous recombination indicated by larger Xs. In the targeted locus shown at the bottom, *lacZ* is translated under the control of *Math1* regulatory elements. Figure 7B demonstrates Southern blot analysis of embryonic stem cells using the 3' external probe. The upper band represents wt allele and the lower band the targeted mutant allele (mut) in targeted clones. Figure 7C demonstrates Southern blot analysis of DNA from the progeny of heterozygous mice demonstrating the presence of the targeted allele and absence of the wild-type allele in *Math1*^{b-gal/b-gal} mice (asterisks). The abbreviations are as follows: (A) ApaI; (H) HindIII; (RI) EcoRI; (S) SalI; and (X) XbaI.

Figures 8A through 8H show *Math1/lacZ* expression and cerebellar phenotype in *Math1*^{+/b-gal} and *Math1*^{b-gal/b-gal} mice. Figure 8A shows *Math1/lacZ* expression in the dorsal neural tube at E9.5 and (Figure 8B) E10.5. Figure 8C indicates a section through the hind brain at E10.5 has *Math1/lacZ* expression in the dorsal portion (arrows). Figure 8D demonstrates that in a spinal cord section from E12.5 embryo, dorsal cells migrate ventrally (arrows). Figure 8E shows at E14.5 expression is observed in the EGL progenitors at the rhombic lip and in migrating cells that will populate the EGL. Figure 8F demonstrates in *Math1*^{b-gal/b-gal} mice, *Math1/lacZ* expression is limited to a few cells in the rhombic lip, which is significantly reduced in size. Figure 8G shows that at P0

Math1/lacZ is expressed in the EGL. Figure 8H demonstrates that the EGL is absent in the null mice. Original magnification for Figures 8C through 8H was 100x.

Figure 9A through 9G shows expression of *Math1/lacZ* in the inner ear and brain stem and histological analysis of ventral pontine nucleus. X-gal staining of E18.5 *Math1*^{+/-b-gal} utricular crista (Figure 9A) and inner ear sensory epithelia of *Math1*^{+/-b-gal} (Figure 9B) and *Math1*^{b-gal/b-gal} (Figure 9C). The *Math1/lacZ* expression in the upper hair cell layer of the sensory epithelia of (Figures 9A and 9B) and the characteristic calyx appearance (arrowhead). In the null mice X-gal staining of epithelial cells is non-specific in the absence of hair cells (Figure 9C). Whole-brain X-gal staining of *Math1*^{+/-b-gal} (Figure 9D) and *Math1*^{b-gal/b-gal} (Figure 9E) at E18.5 is demonstrated. There is positive staining of the pontine nucleus (arrowhead) and cerebellum (arrow) in *Math1*^{+/-b-gal} mice, which is lacking or greatly reduced in null mutants in both the cerebellum, and pontine nucleus (inset). Figures 9F and 9G show haematoxylin and eosin staining of sagittal sections through the pons of a wild type and null mutant (Figures 9F and 9G, respectively), showing the loss of the ventral pontine nucleus in null mutants. The original magnifications were as follows: (A) 400x (B & C) 1000x, (D & E) 8x, inset in D & E 100x, (F & G) 10x.

Figures 10A through 10E demonstrate *Math1/lacZ* is expressed in joint chondrocytes. X-gal staining of whole embryos at (Figure 10A) E12.5 and (Figure 10B) E16.5 illustrates that *Math1/lacZ* is expressed in all joints (Figure 10C). Horizontal section through the elbow joint of E18.5 *Math1*^{+/-b-gal} mouse shows that it is expressed in resting chondrocytes (arrow). Figure 10D shows a horizontal section through a humero-radial joint at P10 that has expression in the articular chondrocytes (arrowhead)

and resting chondrocytes (arrow). Figure 10E shows high magnification of a section through a wrist joint indicating *Math1/lacZ* is expressed in articular chondrocytes. The original magnification is was follows: (C) 10x; (D) 20x; and (E) 40x.

Figures 11A through 11L show *Math1/lacZ* expression in Merkel cells. To
5 identify the structures stained on the hairy and non-hairy skin, E16.5 littermate embryos were stained as whole mounts, sectioned, and microscopically examined. Shown are sections through the vibrissae (Figure 11A), foot pad at low (Figure 11B) and high magnification of the region marked by an arrow in B (Figure 10C), and hairy skin (Figure 11D). In all sections the localization of the stained cells was as expected from Merkel
10 cells. To look for macroscopic defects in null mice, close-up pictures were taken through a stereomicroscope of *Math1*^{+/-b-gal} (control, panels E-H) and *Math1*^{b-gal/b-gal} (null, panels I-L) littermate mice. Staining in null mice appeared stronger because of a dosage effect in the vibrissae (E, I), limb joints (F, J), and foot pads (G, K). In contrast, the staining intensity of null (J, L) mice was markedly weaker than that of heterozygous (F, H) mice
15 in the touch domes associated with the hairy skin. The original magnification is was follows: A x200; B x50; C x400; D x500; E-G-H-I-K-L x32; F-J x16.

Figures 12A through 12E show lack of *lacZ*-stained touch domes in *Tabby* mice. *Tabby/Tabby* females were crossed with *Math1*^{+/-b-gal} males, and their progeny were X-gal stained and gender-determined at E16.5. Staining around primary vibrissae in the snout
20 was detected in both female embryos heterozygous for the *Tabby* mutation (Figure 12A) and male embryos hemizygous for the mutation (Figure 12B). Secondary vibrissae, which are known to vary in number in the *Tabby* mutants (black arrows), were also stained. The staining of the touch domes was less intense in the *Tabby/X* female (Figure

12D) than *Math1*^{+/b-gal} (wt for *Tabby*) embryos (Figure 12C), since *Tabby* is a semidominant mutation. However, patches of stained touch domes were detected in a female embryo that carried a wild-type allele at the *Tabby* locus (Figure 12A, red arrow, and 12D). In contrast, a hemizygous male completely lacked both staining and touch domes, due to the loss of hair follicles that abolishes the development of Merkel cells (Figures 12B and 12E).

Figures 13 A through 13F demonstrate marker analysis of Merkel cells in wild type and *Math1* null mice. Skin sections from *Math1*^{+/+} and *Math1*^{b-gal/b-gal} reacted with antibodies against MATH1 (Figures 13A and 13B), cytokeratin 18 (Figures 13C and 13D), and chromogranin A (Figures 13E and 13F). Polyclonal antibodies to MATH1 identify multiple basal nuclei in rare abdominal hair follicles of wild type (Figure 13A) but not mutant mice (Figure 13B). Monoclonal antibodies to cytokeratin 18 and chromogranin A identify Merkel cells in both wild type (Figures 13C and 13E) and mutant (Figures 13D and 13F) mice. The original magnification was 100X.

Figures 14A through 14G show *Math1* rescues the lack of chordotonal neurons in *Drosophila ato* mutant embryos. Figure 14A shows a dorsal view of the thorax of a wild-type fly. Note there are regular array of bristles or macrochaetae. Figure 14B shows a similar view of a transgenic fly in which *Math1* was overexpressed using the UAS/GAL4 system (Brand and Perrimon, 1993). This ectopic expression leads to numerous extra bristles that are external sensory organs (another type of mechano receptor), not CHOs. Ectopic CHOs were produced in many other regions. Figure 14C shows a lateral view of two abdominal clusters containing 6 CHOs in addition to external sensory organs, revealed by a neuronal-specific antibody (Mab 22C10). The 5 lateral

CHOs form a cluster, and the sixth is dorsal to the cluster. Figure 14D shows a similar view of an *ato* mutant embryo showing lack of the CHOs. Figure 14E demonstrates ubiquitous expression of *Math1* induces new CHO neurons in *ato* mutant embryos in the proper location. Figure 14F shows *in situ* hybridization of whole mount third instar brain using the *ato* cDNA as a probe. Note expression in the developing optic lobes ("horse shoe" expression patterns) and two punctate clusters of cells in the middle of the brain lobes (arrow heads). Figure 14G shows *Math1* expression in *Drosophila* induces CHO formation in normal and ectopic locations. The (+) indicates presence of CHOs and (-) indicates their absence. Number of (+) in the first column is used to quantify the relative increase in the number of CHOs observed when *Math1* is expressed.

DETAILED DESCRIPTION OF THE INVENTION

It is readily apparent to one skilled in the art that various embodiments and modifications can be made to the invention disclosed in this Application without departing from the scope and spirit of the invention.

The term "abnormal proliferation" as used herein is defined as any proliferation of any type of cell, wherein said cell is not under the constraints of normal cell cycle progression and wherein said proliferation can result in a tumor or any cancerous development.

The term "alteration" as used herein is defined as any type of change or modification to a nucleic acid or amino acid. Said change or modification includes any mutation, deletion, rearrangement, addition to a nucleic acid. This includes posttranscriptional processing such as addition of a 5' cap, intron processing and

polyadenylation. Mutations can be nonsense, missense, frameshift, or could lead to a truncated amino acid or could alter the conformation of the amino acid. The alteration to a nucleic acid can be present in regulatory sequences or can affect *trans*-acting factors. Also, multiple alterations can be present. Said change or modification also includes any
5 change to an amino acid including methylation, myristilation, acetylation, glycosylation, or a change to signals associated with processing of said amino acid including intracellular or intercellular localization signals and cleaving of extraneous amino acids. Said alteration can also affect degradation or folding of said protein.

The term “*atonal*-associated” as used herein is defined as any nucleic acid
10 sequence or amino acid sequence which is the *Drosophila atonal* nucleic acid sequence or amino acid sequence, or is any sequence which is homologous to or has significant sequence similarity to said nucleic acid or amino acid sequence, respectively. The sequence can be present in any animal including mammals and insects. As used herein, significant sequence similarity means similarity is greater than 25% and can occur in any
15 region of another sequence. Examples of *atonal*-associated include but are not limited to *Math1* (mouse a*tonal* homolog 1), *Cath1* (chicken a*tonal* homolog 1), *Hath1* (human a*tonal* homolog 1), and *Xath1* (Xenopus a*tonal* homolog 1). Furthermore, multiple homologous or similar sequences can exist in an animal.

The term “cerebellar granule neuron deficiencies” as used herein is defined as any
20 deficiency associated with cerebellar granule neurons and can include loss of cerebellar granule neurons, cerebellar granule neuron precursor cells, lack of granule cell proliferation, lack of granule cell migration and lack of cerebellar external granule layer cells.

The term “defect” as used herein is defined as an alteration, mutation, flaw or loss of expression of an *atonal*-associated sequence. A skilled artisan is aware that loss of expression concerns expression levels of an *atonal*-associated sequence which are not significant or detectable by standard means in the art. A skilled artisan is also aware that
5 loss, or absence, of expression levels in an adult organism, such as a human, occurs naturally and leads to impairment of hearing over time. Thus, “defect” as used herein includes the natural reduction or loss of expression of an *atonal*-associated sequence.

The term “delivering” as used herein is defined as bringing to a destination and includes administering, as for a therapeutic purpose.

10 The term “delivery vehicle” as used herein is defined as an entity which is associated with transfer of another entity. Said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof.

15 The term “detectable condition” as used herein is defined as any state of health or status of an animal, organ or tissue characterized by specific developmental or pathological symptoms. Examples include but are not limited to loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, imbalance, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation
20 of medulloblastoma.

The term “heterologous” as used herein is defined as nucleic acid sequence which is of or relating to nucleic acid sequence not naturally occurring in a particular locus. In an alternative embodiment, the heterologous nucleic acid sequence naturally occurs in

a particular locus, but contains a molecular alteration compared to the naturally occurring locus. For instance, a wild-type locus of an *atonal*-associated sequence can be used to replace a defective copy of the same sequence.

The term “imbalance disorder” as used herein is defined as a medical condition wherein an organism has impaired balance. In a specific embodiment the impairment is due to a defect of vestibular origin. In another specific embodiment the disorder is a vestibular disorder of balance perception including but not limited to Meniere disease, vertigo and layrinthitis.

The term “inactivated” as used herein is defined as a state in which expression of a nucleic acid sequence is reduced or completely eliminated. Said inactivation can occur by transfer or insertion of another nucleic acid sequence or by any means standard in the art to affect expression levels of a nucleic acid sequence.

The term “precursors” as used herein is defined as progenitor cells from which other cells derive their origin and/or properties.

The term “regulatable reporter sequence” as used herein is defined as any sequence which directs transcription of another sequence and which itself is under regulatory control by an extrinsic factor or state. Examples of extrinsic factors or states include but are not limited to exposure to chemicals, nucleic acids, proteins, peptides, lipids, carbohydrates, sugars, light, sound, hormones, touch, or tissue-specific milieu. Examples of regulatable reporter sequences include the GAL promoter sequence and the tetracycline promoter/transactivator sequence.

The term “regulatory sequence” as used herein is defined as any sequence which controls either directly or indirectly the transcription of another sequence. Said control

can be either regarding the initiation or cessation of transcription or regarding quantity or tissue distribution of transcription.

The term “reporter sequence” as used herein is defined as any sequence which demonstrates expression by a regulatory sequence. Said reporter sequence can be used
5 as a marker in the form of an RNA or in a protein. Examples of reporter sequences are b-galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase, b-glucuronidase and chloramphenicol transferase (CAT). In a specific aspect of the present invention, the presence and quantity of the reporter sequence product, whether it be a nucleic acid or amino acid, reflects the level
10 of transcription by the promoter sequence which regulates it.

The term “therapeutically effective” as used herein is defined as the amount of a compound required to improve some symptom associated with a disease. For example, in the treatment of hearing impairment, a compound which improves hearing to any degree or arrests any symptom of hearing impairment would be therapeutically effective.
15 In the treatment of a joint disease, a compound which improves the health or movement of a joint to any degree or arrests any symptom of a joint disease would be therapeutically effective. In the treatment of abnormal proliferation of cells, a compound which reduces the proliferation would be therapeutically effective. In the treatment of cancer, a compound which reduces proliferation of the cells, reduces tumor size, reduces
20 metastases, reduces proliferation of blood vessels to said cancer, facilitates an immune response against the cancer would be therapeutically effective, for example. A therapeutically effective amount of a compound is not required to cure a disease but will provide a treatment for a disease.

The term “vector” as used herein is defined as a biological vehicle for delivery of a specific entity. In a specific embodiment the entity is an *atonal*-associated nucleic acid.

5 In one aspect of the present invention there are methods and reagents which include utilization of an *atonal*-associated nucleic acid or amino acid sequence for the therapeutic use of detectable conditions such as loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation
10 of medulloblastoma. Thus, any homolog or ortholog of *atonal* (from *Drosophila*) including but not limited to *Cath1* (from chicken), *Hath1* (from human), *Math1* (from mice) or *Xath1* (from *Xenopus*) can be used in the present invention. In a preferred embodiment these sequences are directed to treatment of an animal, specifically a human, for the detectable conditions stated above. It is within the scope of the invention to
15 encompass any sequence which is homologous to or has significant sequence similarity to said nucleic acid or amino acid sequence, respectively. The sequence can be present in any animal including mammals and insects. As used herein, significant sequence similarity means similarity (identity of amino acid residues or nucleic acid bases) is greater than 25% and can occur in any region of the sequence. In another embodiment
20 an *atonal*-associated sequence as used herein has greater than about 50% sequence similarity, greater than about 70% similarity, or greater than about 80% similarity.

It is within the scope of the present invention that an *atonal*-associated nucleic acid sequence or amino acid sequence is utilized wherein domains important for activity,

such as the basic HLH region, are included in a molecule but further comprise alterations, mutations, deletions or substitutions in regions of the nucleic acid or amino acid sequence which are not part of a domain important for an activity and do not affect its function.

Examples of *atonal*-associated include but are not limited to *Math1* (mouse atonal
5 homolog 1), *Cath1* (chicken atonal homolog 1), *Hath1* (human atonal homolog 1), and
Xath1 (Xenopus atonal homolog 1). Such examples are represented in SEQ ID NO:1
through SEQ ID NO:66, although others very likely exist in related organisms. A skilled
artisan is cognizant of means to identify such sequences which have significant
similarity, such as searching database collections of nucleic and amino acid sequence
10 located on the World Wide Web, including
<http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html>.

The sequences provided herein and the corresponding GenBank Accession
numbers are listed parenthetically as follows: SEQ ID NO:1 (NM_005172); SEQ ID
NO:2 (NP_005163.1); SEQ ID NO:3 (AW413228); SEQ ID NO: 4 (NM_009719); SEQ
15 ID NO:5 (NP_033849.1); SEQ ID NO:6 (NM_009718); SEQ ID NO: 7 (NP_033848.1)
SEQ ID NO:8 (NM_009717); SEQ ID NO: 9 (NP_033847.1); SEQ ID NO:10
(NM_007500); SEQ ID NO: 11(NP_031526.1); SEQ ID NO:12 (NM_007501); SEQ ID
NO:13 (AW280518); SEQ ID NO:14(AW236965); SEQ ID NO:15(AW163683); SEQ
ID NO:16 (AF134869); SEQ ID NO: 17(AAD31451.1); SEQ ID NO:18 (AJ012660);
20 SEQ ID NO:19 (CAA10106.1); SEQ ID NO:20 (AJ012659); SEQ ID NO:21
(CAA10105.1); SEQ ID NO:22 (AF071223); SEQ ID NO:23 (AAC68868.1); SEQ ID
NO:24 (U76208); SEQ ID NO:25 (AAC53029.1); SEQ ID NO:26 (U76210); SEQ ID
NO:27 (AAC53033.1); SEQ ID NO:28 (U76209); SEQ ID NO:29 (AAC53032.1); SEQ

ID NO:30 (U76207); SEQ ID NO:31 (AAC53028.1); SEQ ID NO:32 (AF036257); SEQ
 ID NO:33 (AAC15969.1); SEQ ID NO:34 (AF034778); SEQ ID NO:35 (AJ001178);
 SEQ ID NO:36 (CAA04572.1); SEQ ID NO:37 (Y07621); SEQ ID NO:38
 (CAA68900.1); SEQ ID NO:39 (AF024536); SEQ ID NO:40 (AAB82272.1); SEQ ID
 5 NO:41 (D85188); SEQ ID NO:42 (BAA12738.1); SEQ ID NO:43 (D44480); SEQ ID
 NO:44(BAA07923.1); SEQ ID NO:45 (D43694); SEQ ID NO:46 (BAA07791.1); SEQ
 ID NO:47 (D85845); SEQ ID NO:48 (BAA12880.1); SEQ ID NO:49 (U93171); SEQ ID
 NO:50 (AAB58669.1); SEQ ID NO:51 (U93170); SEQ ID NO:52 (AAB58668.1); SEQ
 ID NO:53 (U61152); SEQ ID NO:54 (AAB41307.1); SEQ ID NO:55 (U61151); SEQ ID
 10 NO:56 (AAB41306.1); SEQ ID NO:57 (U61148); SEQ ID NO:58 (AAB41305.1); SEQ
 ID NO:59 (U61149); SEQ ID NO:60 (AAB41304.1); SEQ ID NO:61 (U61150); SEQ ID
 NO:62 (AAB41303.1); SEQ ID NO:63 (L36646); and SEQ ID NO:64 (AAA21879.1).

In an aspect of the invention there is an animal having a heterologous nucleic acid
 sequence replacing an allele of an *atonal*-associated nucleic acid sequence under
 15 conditions wherein said heterologous sequence inactivates said allele. In an alternative
 embodiment a heterologous sequence is delivered to a cell for extrachromosomal
 propagation. In another alternative embodiment a heterologous sequence is integrated
 into the chromosome of a cell in a locus other than the locus of an *atonal*-associated
 nucleic acid sequence. In a preferred embodiment said heterologous sequence is
 20 expressed under control of an *atonal*-associated regulatory sequence. In a specific
 embodiment both *atonal*-associated alleles are replaced. In an additional specific
 embodiment both *atonal*-associated alleles are replaced with nonidentical heterologous
 nucleic acid sequences. Methods to generate transgenic animals are well known in the

art, and a skilled artisan would refer to such references as Transgenic Animals by Grosveld and Kollias (eds.) or Mouse Genetics and Transgenics : A Practical Approach by Jackson et al. (eds.).

5 In an additional embodiment a transgenic animal of the present invention has a detectable condition wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis and abnormal proliferation of cells. In another embodiment of the present invention a heterologous nucleic acid sequence is a reporter
10 sequence selected from the group consisting of β -galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase, β -glucuronidase and chloramphenicol transferase (CAT). In another specific embodiment, a reporter sequence is regulatable or is expressed in brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear epithelial cells and
15 brain stem nuclei. In additional specific embodiments said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under control of a regulatable promoter sequence or a tissue-specific promoter sequence wherein said tissue is selected from the group consisting of brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear epithelial cells and brain stem nuclei.
20 In additional embodiments a transgenic animal is a mouse, *Drosophila*, frog, zebrafish, rat, guinea pig, or hamster.

 In another embodiment of the present invention is a method for screening for a compound in an animal, wherein said compound affects expression of an *atonal*-

associated nucleic acid sequence comprising delivering said compound to said animal wherein said animal has at least one allele of an *atonal*-associated nucleic acid sequence inactivated by insertion of a heterologous nucleic acid sequence wherein said heterologous nucleic acid sequence is under control of an *atonal*-associated regulatory
5 sequence, and monitoring for a change in said expression of said *atonal*-associated nucleic acid sequence. Examples of regulatory sequences can include promoter sequences, enhancers or silencers.

In specific embodiments there is a compound which upregulates or downregulates said expression of an *atonal*-associated nucleic acid sequence. The upregulation or
10 downregulation can be by increasing the rate of transcription or decreasing the rate of mRNA decay.

Another embodiment of the present invention is a compound which affects expression of an *atonal*-associated nucleic acid sequence. In specific embodiments said compound upregulates or downregulates expression of an *atonal*-associated nucleic acid
15 sequence. In a specific embodiment said compound affects a detectable condition in an animal wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis, abnormal proliferation of cells and formation of cancer.

Another embodiment of the present invention is a method for screening for a
20 compound in an animal, wherein the compound affects a detectable condition in the animal, comprising delivering the compound to the animal wherein at least one allele of an *atonal*-associated nucleic acid sequence in said animal is inactivated by insertion of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence

is under the control of an *atonal*-associated regulatory sequence, and monitoring said animal for a change in the detectable condition. In a specific embodiment said detectable condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis and abnormal proliferation of cells. In another embodiment said delivery of said compound affects expression of said heterologous nucleic acid sequence. In specific embodiments said expression of said heterologous nucleic acid sequence is upregulated or downregulated. In additional specific embodiments the animal is a mouse, *Drosophila*, frog, zebrafish, rat, hamster and guinea pig.

Another embodiment of the present invention is a compound wherein said compound affects a detectable condition in a transgenic animal of the present invention. In specific embodiments said compound affects expression of a heterologous nucleic acid sequence. In additional specific embodiments said compound upregulates or downregulates expression of a heterologous nucleic acid sequence.

In other embodiments of the present invention are methods of treating an animal, including a human, for cerebellar granule neuron deficiencies, for promoting mechanoreceptive cell growth, for generating hair cells, for treating hearing impairment or an imbalance disorder, for treating a joint disease, for treating for an abnormal proliferation of cells, and for treating for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence. Said methods include administering a therapeutically effective amount of an *atonal*-associated nucleic acid or amino acid sequence. In specific embodiments said administration is by a vector selected from the group consisting of a viral vector (including bacteriophage, animal and plant

viruses), a plasmid, cosmid or any other nucleic acid based vector, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof of said vectors. In a specific embodiment said viral vector is an adenovirus vector, a retrovirus vector, or an adeno-associated vector, including a lentivirus vector, Herpes virus vector, alpha virus vector, *etc.* Thus, a vector can be viral or non-viral. In another specific embodiment said vector is a cell. In a preferred embodiment said vector is an adenovirus vector comprising a cytomegalovirus IE promoter sequence and a SV40 early polyadenylation signal sequence. In another specific embodiment said cell is a human cell. In an additional specific embodiment said joint disease is osteoarthritis.

In an embodiment of the present invention there is provided a method for treating an organism for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence. A skilled artisan is aware that this loss can be due to natural reduction or absence of significant (or to detectable levels) expression which occurs in an adult human.

In a specific embodiment, the present invention also provides a method of treating an animal in need of treatment for a deficiency in cerebellar granule neurons, a hearing impairment, an imbalance disorder, a joint disease, or in need of promoting mechanoreceptive cell growth, or a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequences. This method comprises delivering a transcription factor having an amino acid with at least about 70% identity, preferably at least about 80% identity, and more preferably at least about 90% identity to the sequence AANARERRRMHGLNHAFDQLR to a cell in the animal. In some embodiments, the cell in the animal is located in the inner ear of the animal. Preferably, the transcription

factor competes with *atonal* for binding to Daughterless protein (Jarman et al., 1993) or competes for binding with Math-1 to E47 protein (Akazawa et al., 1995).

In another embodiment of the present invention is a method for treating an animal for an abnormal proliferation of cells comprising altering *atonal*-associated nucleic acid or amino acid sequence levels in a cell. In a specific embodiment said alteration is reduction or said nucleic acid or amino acid sequence contains an alteration.

In a preferred embodiment of the present invention there are compositions to treat an organism for various medical conditions, discussed herein, comprising an *atonal*-associated nucleic acid sequence or amino acid sequence in combination with a delivery vehicle, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. A skilled artisan is aware that an adult organism, such as an adult human, naturally does not express *atonal* to significant or detectable levels, but instead expresses *atonal* in an embryonic stage of development (see the Examples). Thus, in a preferred embodiment, compositions to treat an organism as discussed herein, include compositions to treat organisms who do not contain a mutation in an *atonal* nucleic acid or amino acid sequence but who naturally have *atonal* no longer expressed to significant or detectable levels.

In another embodiment of the present invention is a composition comprising an *atonal*-associated amino acid sequence or nucleic acid sequence in combination with a delivery vehicle wherein said vehicle delivers a therapeutically effective amount of an *atonal*-associated nucleic acid sequence or amino acid sequence into a cell. In specific embodiments said vehicle is the receptor-binding domain of a bacterial toxin or any

fusion molecule or is a protein transduction domain. In a specific embodiment said protein transduction domain is from the HIV TAT peptide.

In another embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the

present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

5 In another embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a
10 composition to treat an organism for hearing impairment, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an amino acid sequence which is associated with
15 regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for an imbalance disorder, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific
20 embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for an imbalance disorder, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an

atonal-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for an imbalance disorder, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

5 In another embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic
10 acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism
15 comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or
20 alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises

defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an

5 *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific

10 embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the

15 present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an *atonal*-associated

20 nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an

organism for cancer, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In a specific embodiment said cancer is medulloblastoma.

NUCLEIC ACID-BASED EXPRESSION SYSTEMS

1. Vectors

One of skill in the art would be well equipped to construct a vector through standard recombinant techniques, which are described in Sambrook et al., 1989 and Ausubel et al., 1994, both incorporated herein by reference.

The term "expression vector" refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors can

contain nucleic acid sequences that serve other functions as well and are described *infra*.

a. Promoters and Enhancers

5 A "promoter" is a control sequence that is a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It can contain genetic elements at which regulatory proteins and molecules can bind such as RNA polymerase and other transcription factors. A promoter may or may not be used in conjunction with an "enhancer," which refers to a *cis*-acting regulatory sequence involved in the
10 transcriptional activation of a nucleic acid sequence.

Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the cell type, organelle, and organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression,
15 for example, see Sambrook et al. (1989), incorporated herein by reference. The promoters employed can be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides. The promoter can be heterologous or endogenous.

20 The identity of tissue-specific promoters or elements, as well as assays to characterize their activity, is well known to those of skill in the art. Examples of such regions include the human LIMK2 gene (Nomoto et al. 1999), the somatostatin receptor 2 gene (Kraus et al., 1998), murine epididymal retinoic acid-binding gene (Lareyre et al.,

1999), human CD4 (Zhao-Emonet et al., 1998), mouse alpha2 (XI) collagen (Tsumaki, et al., 1998), D1A dopamine receptor gene (Lee, et al., 1997), insulin-like growth factor II (Wu et al., 1997), human platelet endothelial cell adhesion molecule-1 (Almendo et al., 1996).

5

b. Initiation Signals and Internal Ribosome Binding Sites

A specific initiation signal also can be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, can need
10 to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression can be enhanced by the
15 inclusion of appropriate transcription enhancer elements.

In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By
20 virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Patent 5,925,565 and 5,935,819, herein incorporated by reference).

c. Multiple Cloning Sites

Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector. (See Carbonelli et al., 1999, 5 Levenson et al., 1998, and Cocea, 1997, incorporated herein by reference.)

d. Splicing Sites

Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. Vectors containing genomic eukaryotic 10 sequences can require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression. (See Chandler et al., 1997, herein incorporated by reference.)

e. Polyadenylation Signals

15 In expression, one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. Specific embodiments include the SV40 polyadenylation signal and/or the bovine growth hormone polyadenylation signal, convenient and/or known to function well in various target cells.

20 **f. Origins of Replication**

In order to propagate a vector in a host cell, it can contain one or more origins of replication sites (often termed "ori"), which is a specific nucleic acid sequence at which replication is initiated.

g. Selectable and Screenable Markers

In certain embodiments of the invention, the cells contain nucleic acid construct of the present invention, a cell can be identified *in vitro* or *in vivo* by including a marker in the expression vector. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP or enhanced GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) can be utilized. One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. Further examples of selectable and screenable markers are well known to one of skill in the art.

2. Expression Systems

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and
5 widely available.

The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patent No. 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC® 2.0 from INVITROGEN® and BACPACK™
10 BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH®. Other examples of expression systems are well known in the art.

Nucleic Acid Detection

In addition to their use in directing the expression of atonal-associated proteins,
15 polypeptides and/or peptides, the nucleic acid sequences disclosed herein have a variety of other uses. For example, they have utility as probes or primers or in any of the methods for embodiments involving nucleic acid hybridization, amplification of nucleic acid sequences, detection of nucleic acids, and other assays. A skilled artisan is aware of the following patents regarding details of these methods: U.S. Patent No. 5,840,873;
20 U.S. Patent No. 5,843, 640; U.S. Patent No. 5,843,650; U.S. Patent No. 5,843,651; U.S. Patent No. 5,843,663; U.S. Patent No. 5,846,708; U.S. Patent No. 5,846,709; U.S. Patent No. 5,846,717; U.S. Patent No. 5,846,726; U.S. Patent No. 5,846,729; U.S. Patent No. 5,846,783; U.S. Patent No. 5,849,481; U.S. Patent No. 5,849,483; U.S. Patent No.

5,849,486; U.S. Patent No. 5,849,487; U.S. Patent No. 5,849,497; U.S. Patent No. 5,849,546; U.S. Patent No. 5,849,547; U.S. Patent No. 5,851,770; U.S. Patent No. 5,851,772; U.S. Patent No. 5,853,990; U.S. Patent No. 5,853, 993; U.S. Patent No. 5,853,992; U.S. Patent No. 5,856,092; U.S. Patent No. 5,858,652; U.S. Patent No. 5,861,244; U.S. Patent No. 5,863,732; U.S. Patent No. 5,863,753; U.S. Patent No. 5,866,331; U.S. Patent No. 5,866,336; U.S. Patent No. 5,866,337; U.S. Patent No. 5,900,481; U.S. Patent No. 5,905,024; U.S. Patent No. 5,910,407; U.S. Patent No. 5,912,124; U.S. Patent No. 5,912,145; U.S. Patent No. 5,912,148; U.S. Patent No. 5,916,776; U.S. Patent No. 5,916,779; U.S. Patent No. 5,919,626; U.S. Patent No. 5,919,630; U.S. Patent No. 5,922, 574; U.S. Patent No. 5,925,517; U.S. Patent No. 5,925,525; U.S. Patent No. 5,928,862; U.S. Patent No. 5,928,869; U.S. Patent No. 5,928,870; U.S. Patent No. 5,928,905; U.S. Patent No. 5,928,906; U.S. Patent No. 5,929,227; U.S. Patent No. 5,932,413; U.S. Patent No. 5,932,451; U.S. Patent No. 5,935,791; U.S. Patent No. 5,935,825; U.S. Patent No. 5,939,291; U.S. Patent No. 5,942,391; European Application No. 320 308; European Application No. 329 822; GB Application No. 2 202 328; PCT Application No. PCT/US87/00880; PCT Application No. PCT/US89/01025; PCT Application WO 88/10315; PCT Application WO 89/06700; and PCT Application WO 90/07641.

20 Kits

All the essential materials and/or reagents required for detecting a sequence selected from SEQ ID NO:1 through SEQ ID NO:66 in a sample can be assembled together in a kit. This generally will comprise a probe or primers designed to hybridize

specifically to individual nucleic acids of interest in the practice of the present invention, such as the nucleic acid sequences in SEQ ID NO:1 through SEQ ID NO:66. Also included can be enzymes suitable for amplifying nucleic acids, including various polymerases (reverse transcriptase, Taq, etc.), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification. Such kits can also include enzymes and other reagents suitable for detection of specific nucleic acids or amplification products. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or enzyme as well as for each probe or primer pair.

Atonal-Associated Nucleic Acids

A. Nucleic Acids and Uses Thereof

A nucleic acid can be purified on polyacrylamide gels, cesium chloride centrifugation gradients, or by any other means known to one of ordinary skill in the art (see for example, Sambrook et al. 1989, incorporated herein by reference).

The term "nucleic acid" will generally refer to at least one molecule or strand of DNA, RNA or a derivative or mimic thereof, comprising at least one nucleobase, such as, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g. adenine "A," guanine "G," thymine "T" and cytosine "C") or RNA (e.g. A, G, uracil "U" and C). The term "nucleic acid" encompass the terms "oligonucleotide" and "polynucleotide." The term "oligonucleotide" refers to at least one molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length. These definitions

generally refer to at least one single-stranded molecule, but in specific embodiments will also encompass at least one additional strand that is partially, substantially or fully complementary to the at least one single-stranded molecule. Thus, a nucleic acid can encompass at least one double-stranded molecule or at least one triple-stranded molecule
5 that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a strand of the molecule. As used herein, a single stranded nucleic acid can be denoted by the prefix "ss", a double stranded nucleic acid by the prefix "ds", and a triple stranded nucleic acid by the prefix "ts."

Thus, the present invention also encompasses at least one nucleic acid that is
10 complementary to a atonal-associated nucleic acid. In particular embodiments the invention encompasses at least one nucleic acid or nucleic acid segment complementary to the nucleic acid sequences set forth in SEQ ID NO:1 through SEQ ID NO:66, of those which are nucleic acid sequences. Nucleic acid(s) that are "complementary" or "complement(s)" are those that are capable of base-pairing according to the standard
15 Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. As used herein, the term "complementary" or "complement(s)" also refers to nucleic acid(s) that are substantially complementary, as can be assessed by the same nucleotide comparison set forth above. The term "substantially complementary" refers to a nucleic acid comprising at least one sequence of consecutive nucleobases, or semiconsecutive
20 nucleobases if one or more nucleobase moieties are not present in the molecule, are capable of hybridizing to at least one nucleic acid strand or duplex even if less than all nucleobases do not base pair with a counterpart nucleobase.

Herein certain embodiments, a "gene" refers to a nucleic acid that is transcribed.

As used herein, a "gene segment" is a nucleic acid segment of a gene. In certain aspects, the gene includes regulatory sequences involved in transcription, or message production or composition. In particular embodiments, the gene comprises transcribed sequences

5 that encode for a protein, polypeptide or peptide. In other particular aspects, the gene comprises an atonal-associated nucleic acid, and/or encodes an atonal-associated polypeptide or peptide coding sequences. In keeping with the terminology described herein, an "isolated gene" can comprise transcribed nucleic acid(s), regulatory sequences, coding sequences, or the like, isolated substantially away from other such sequences,

10 such as other naturally occurring genes, regulatory sequences, polypeptide or peptide encoding sequences, etc. In this respect, the term "gene" is used for simplicity to refer to a nucleic acid comprising a nucleotide sequence that is transcribed, and the complement thereof. In particular aspects, the transcribed nucleotide sequence comprises at least one functional protein, polypeptide and/or peptide encoding unit. As will be

15 understood by those in the art, this function term "gene" includes both genomic sequences, RNA or cDNA sequences or smaller engineered nucleic acid segments, including nucleic acid segments of a non-transcribed part of a gene, including but not limited to the non-transcribed promoter or enhancer regions of a gene. Smaller engineered gene nucleic acid segments can express, or can be adapted to express using

20 nucleic acid manipulation technology, proteins, polypeptides, domains, peptides, fusion proteins, mutants and/or such like.

In certain embodiments, the nucleic acid sequence is a nucleic acid or nucleic acid segment. As used herein, the term "nucleic acid segment", are smaller fragments of

a nucleic acid, such as for non-limiting example, those that encode only part of the atonal-associated peptide or polypeptide sequence. Thus, a "nucleic acid segment" can comprise any part of the atonal-associated gene sequence(s), of from about 2 nucleotides to the full length of the atonal-associated peptide or polypeptide encoding region. In certain embodiments, the "nucleic acid segment" encompasses the full length atonal-associated gene(s) sequence. In particular embodiments, the nucleic acid comprises any part of the SEQ ID NO:1 through SEQ ID NO:66, of from about 2 nucleotides to the full length of the sequence disclosed in SEQ ID NO:1 through SEQ ID NO:66.

In certain embodiments, the nucleic acid segment can be a probe or primer. As used herein, a "probe" is a nucleic acid utilized for detection of another nucleic acid and is generally at least about 10 nucleotides in length. As used herein, a "primer" is a nucleic acid utilized for polymerization of another nucleic acid is generally at least about 10 nucleotides in length. A non-limiting example of this would be the creation of nucleic acid segments of various lengths and sequence composition for probes and primers based on the sequences disclosed in SEQ ID NO:1 through SEQ ID NO:66, of those which are nucleic acid sequences.

The nucleic acid(s) of the present invention, regardless of the length of the sequence itself, can be combined with other nucleic acid sequences, including but not limited to, promoters, enhancers, polyadenylation signals, restriction enzyme sites, multiple cloning sites, coding segments, and the like, to create one or more nucleic acid construct(s). As used herein, a "nucleic acid construct" is a recombinant molecule comprising at least two segments of different nucleic acid sequence. The overall length can vary considerably between nucleic acid constructs. Thus, a nucleic acid segment of

almost any length can be employed, with the total length preferably being limited by the ease of preparation or use in the intended recombinant nucleic acid protocol.

In certain embodiments, the nucleic acid construct is a recombinant vector. As used herein, a "recombinant vector" is a nucleic acid comprising multiple segments of nucleic acids utilized as a vehicle for a nucleic acid sequence of interest. In certain aspects, the recombinant vector is an expression cassette. As used herein, an expression cassette is a segment of nucleic acid which comprises a gene of interest which can be transferred between different recombinant vectors by means well known in the art.

In particular embodiments, the invention concerns one or more recombinant vector(s) comprising nucleic acid sequences that encode an atonal-associated protein, polypeptide or peptide that includes within its amino acid sequence a contiguous amino acid sequence in accordance with, or essentially as set forth in, SEQ ID NO:2 through SEQ ID NO:66, of which sequences are amino acid sequences, corresponding to *Homo sapiens* or *Mus musculus* atonal-associated sequence.. In other embodiments, the invention concerns recombinant vector(s) comprising nucleic acid sequences from other species that encode an atonal-associated protein, polypeptide or peptide that includes within its amino acid sequence a contiguous amino acid sequence in accordance with, or essentially as set forth in SEQ ID NO:2 through SEQ ID NO:66, of which sequences are amino acid sequences. In particular aspects, the recombinant vectors are DNA vectors.

It will also be understood that amino acid sequences or nucleic acid sequences can include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, or various combinations thereof, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth

above, including the maintenance of biological protein, polypeptide or peptide activity where expression of a proteinaceous composition is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that can, for example, include various non-coding sequences flanking either of the 5' and/or 3' portions of the coding
5 region or can include various internal sequences, i.e., introns, which are known to occur within genes.

It will also be understood that this invention is not limited to the particular nucleic acid or amino acid sequences of SEQ ID NO: through SEQ ID NO:66, of which sequences are amino acids. Recombinant vectors and isolated nucleic acid segments can
10 therefore variously include these coding regions themselves, coding regions bearing selected alterations or modifications in the basic coding region, and they can encode larger polypeptides or peptides that nevertheless include such coding regions or can encode biologically functional equivalent proteins, polypeptide or peptides that have variant amino acids sequences.

15 The nucleic acids of the present invention encompass biologically functional equivalent atonal-associated proteins, polypeptides, or peptides or atonal-associated proteins, polypeptides or polypeptides. Such sequences can arise as a consequence of codon redundancy or functional equivalency that are known to occur naturally within nucleic acid sequences or the proteins, polypeptides or peptides thus encoded.
20 Alternatively, functionally equivalent proteins, polypeptides or peptides can be created via the application of recombinant DNA technology, in which changes in the protein, polypeptide or peptide structure can be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man can be

introduced, for example, through the application of site-directed mutagenesis techniques as discussed herein below, e.g., to introduce improvements or alterations to the antigenicity of the protein, polypeptide or peptide, or to test mutants in order to examine atonal-associated protein, polypeptide or peptide activity at the molecular level.

5 Fusion proteins, polypeptides or peptides can be prepared, e.g., where the atonal associated coding regions are aligned within the same expression unit with other proteins, polypeptides or peptides having desired functions. Non-limiting examples of such desired functions of expression sequences include purification or immunodetection purposes for the added expression sequences, e.g., proteinaceous compositions that can
10 be purified by affinity chromatography or the enzyme labeling of coding regions, respectively EP 266,032, or via deoxynucleoside H-phosphonate intermediates as described by Froehler et al., Nucl. Acids Res., 14:5399-5407, 1986,

As used herein an "organism" can be a prokaryote, eukaryote, virus and the like. As used herein the term "sequence" encompasses both the terms "nucleic acid" and
15 "proteancecous" or "proteanaceous composition." As used herein, the term "proteinaceous composition" encompasses the terms "protein", "polypeptide" and "peptide." As used herein "artificial sequence" refers to a sequence of a nucleic acid not derived from sequence naturally occurring at a genetic locus, as well as the sequence of any proteins, polypeptides or peptides encoded by such a nucleic acid. A "synthetic
20 sequence", refers to a nucleic acid or proteinaceous composition produced by chemical synthesis *in vitro*, rather than enzymatic production *in vitro* (i.e. an "enzymatically produced" sequence) or biological production *in vivo* (i.e. a "biologically produced" sequence).

Cancer Therapies

Given the present invention is directed to methods and compositions for the treatment of abnormal cell proliferation, a discussion of therapies of cancer, which is the
5 state of abnormal cell proliferation, is warranted.

A wide variety of cancer therapies, such as radiotherapy, surgery, chemotherapy and gene therapy, are known to one of skill in the art, can be used regarding the methods and compositions of the present invention.

10 Radiotherapeutic agents

Radiotherapeutic agents and factors include radiation and waves that induce DNA damage for example, g-irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, radioisotopes, and the like. Therapy can be achieved by irradiating the localized tumor site with the above described forms of radiations.

15 Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

20 Surgery

Surgical treatment for removal of the cancerous growth is generally a standard procedure for the treatment of tumors and cancers. This attempts to remove the entire cancerous growth. However, surgery is generally combined with chemotherapy and/or

radiotherapy to ensure the destruction of any remaining neoplastic or malignant cells. Thus, surgery can be used in the context of the present invention.

Chemotherapeutic Agents

5 These can be, for example, agents that directly cross-link DNA, agents that intercalate into DNA, or agents that lead to chromosomal and mitotic aberrations by affecting nucleic acid synthesis.

 Agents that directly cross-link nucleic acids, specifically DNA, are envisaged and are shown herein, to eventuate DNA damage leading to a synergistic antineoplastic
10 combination. Agents such as cisplatin, and other DNA alkylating agents can be used.

 Agents that damage DNA also include compounds that interfere with DNA replication, mitosis, and chromosomal segregation. Examples of these compounds include adriamycin (also known as doxorubicin), VP-16 (also known as etoposide), verapamil, podophyllotoxin, and the like. Widely used in clinical setting for the
15 treatment of neoplasms these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m² at 21 day intervals for adriamycin, to 35-100 mg/m² for etoposide intravenously or orally.

 Cancer therapies also include a variety of combination therapies with both chemical and other types of treatments. Chemotherapeutics include, for example,
20 cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabine, navelbine,

farnesyl-protein transferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.

Genes

5 Gene Therapy Administration

For gene therapy, a skilled artisan would be cognizant that the vector to be utilized must contain the gene of interest operatively linked to a promoter. For antisense gene therapy, the antisense sequence of the gene of interest would be operatively linked to a promoter. One skilled in the art recognizes that in certain instances other sequences
10 such as a 3' UTR regulatory sequences are useful in expressing the gene of interest. Where appropriate, the gene therapy vectors can be formulated into preparations in solid, semisolid, liquid or gaseous forms in the ways known in the art for their respective route of administration. Means known in the art can be utilized to prevent release and absorption of the composition until it reaches the target organ or to ensure timed-release
15 of the composition. A pharmaceutically acceptable form should be employed which does not ineffectuate the compositions of the present invention. In pharmaceutical dosage forms, the compositions can be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. A sufficient amount of vector containing the therapeutic nucleic acid sequence must be administered to provide
20 a pharmacologically effective dose of the gene product.

One skilled in the art recognizes that different methods of delivery can be utilized to administer a vector into a cell. Examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large

volumes of a liquid (pressure); and (2) methods wherein said vector is complexed to another entity, such as a liposome, viral vector or transporter molecule.

Accordingly, the present invention provides a method of transferring a therapeutic gene to a host, which comprises administering the vector of the present invention, preferably as part of a composition, using any of the aforementioned routes of administration or alternative routes known to those skilled in the art and appropriate for a particular application. Effective gene transfer of a vector to a host cell in accordance with the present invention to a host cell can be monitored in terms of a therapeutic effect (e.g. alleviation of some symptom associated with the particular disease being treated) or, further, by evidence of the transferred gene or expression of the gene within the host (e.g., using the polymerase chain reaction in conjunction with sequencing, Northern or Southern hybridizations, or transcription assays to detect the nucleic acid in host cells, or using immunoblot analysis, antibody-mediated detection, mRNA or protein half-life studies, or particularized assays to detect protein or polypeptide encoded by the transferred nucleic acid, or impacted in level or function due to such transfer).

These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan. Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

Furthermore, the actual dose and schedule can vary depending on whether the compositions are administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. Similarly, amounts can vary in *in vitro* applications depending on the

particular cell line utilized (e.g., based on the number of vector receptors present on the cell surface, or the ability of the particular vector employed for gene transfer to replicate in that cell line). Furthermore, the amount of vector to be added per cell will likely vary with the length and stability of the therapeutic gene inserted in the vector, as well as also
5 the nature of the sequence, and is particularly a parameter which needs to be determined empirically, and can be altered due to factors not inherent to the methods of the present invention (for instance, the cost associated with synthesis). One skilled in the art can easily make any necessary adjustments in accordance with the exigencies of the particular situation.

10 It is possible that cells containing the therapeutic gene can also contain a suicide gene (i.e., a gene which encodes a product that can be used to destroy the cell, such as herpes simplex virus thymidine kinase). In many gene therapy situations, it is desirable to be able to express a gene for therapeutic purposes in a host cell but also to have the capacity to destroy the host cell once the therapy is completed, becomes uncontrollable,
15 or does not lead to a predictable or desirable result. Thus, expression of the therapeutic gene in a host cell can be driven by a promoter although the product of said suicide gene remains harmless in the absence of a prodrug. Once the therapy is complete or no longer desired or needed, administration of a prodrug causes the suicide gene product to become lethal to the cell. Examples of suicide gene/prodrug combinations which can be used are
20 Herpes Simplex Virus-thymidine kinase (HSV-tk) and ganciclovir, acyclovir or FIAU; oxidoreductase and cycloheximide; cytosine deaminase and 5-fluorocytosine; thymidine kinase thymidilate kinase (Tdk::Tmk) and AZT; and deoxycytidine kinase and cytosine arabinoside.

The method of cell therapy can be employed by methods known in the art wherein a cultured cell containing a copy of a nucleic acid sequence or amino acid sequence of *Math1* is introduced.

In yet another embodiment, the secondary treatment is a secondary gene therapy
5 in which a second therapeutic polynucleotide is administered before, after, or at the same
time a first therapeutic polynucleotide encoding all or part of an atonal-associated
polypeptide. Delivery of a vector encoding either a full length or partial atonal-
associated polypeptide in conjunction with a second vector encoding another gene product
will have a combined anti-hyperproliferative effect on target tissues. Alternatively, a
10 single vector encoding both genes can be used.

Immunotherapy

Immunotherapeutics, generally, rely on the use of immune effector cells and
molecules to target and destroy cancer cells. The immune effector can be, for example,
15 an antibody specific for some marker on the surface of a tumor cell. The antibody alone
can serve as an effector of therapy or it can recruit other cells to actually effect cell
killing. The antibody also can be conjugated to a drug or toxin (chemotherapeutic,
radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a
targeting agent. Alternatively, the effector can be a lymphocyte carrying a surface
20 molecule that interacts, either directly or indirectly, with a tumor cell target. Various
effector cells include cytotoxic T cells and NK cells.

Immunotherapy, thus, could be used as part of a combined therapy, in conjunction
with Ad-mda7 gene therapy. The general approach for combined therapy is discussed

below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these can be suitable for targeting in the context of the present invention. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis

5 Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p155.

Combination Treatments

It can be desirable in utilizing the present invention to combine the compositions

10 with other agents effective in the treatment of hyperproliferative disease, such as anti-cancer agents. An "anti-cancer" agent is capable of negatively affecting cancer in a subject, for example, by killing cancer cells, inducing apoptosis in cancer cells, reducing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the blood supply to a tumor or

15 cancer cells, promoting an immune response against cancer cells or a tumor, preventing or inhibiting the progression of cancer, or increasing the lifespan of a subject with cancer. More generally, these other compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell. This process can involve contacting the cells with the expression construct and the agent(s) or multiple factor(s) at the same

20 time. This can be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the expression construct and the other includes the second agent(s).

Tumor cell resistance to chemotherapy and radiotherapy agents represents a major problem in clinical oncology. One goal of current cancer research is to find ways to improve the efficacy of chemo- and radiotherapy by combining it with gene therapy. For example, the herpes simplex-thymidine kinase (HS-tK) gene, when delivered to brain tumors by a retroviral vector system, successfully induced susceptibility to the antiviral agent ganciclovir (Culver, et al., 1992). In the context of the present invention, it is contemplated that mda-7 gene therapy could be used similarly in conjunction with chemotherapeutic, radiotherapeutic, or immunotherapeutic intervention, in addition to other pro-apoptotic or cell cycle regulating agents.

Alternatively, the gene therapy can precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agent and expression construct are applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one can contact the cell with both modalities within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it can be desirable to extend the time period for treatment significantly, however, where several d (2, 3, 4, 5, 6 or 7) to several wk (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

Various combinations can be employed, gene therapy is "A" and the secondary agent, such as radio- or chemotherapy, is "B":

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B

B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A

5 B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A

Administration of the therapeutic expression constructs of the present invention to a patient will follow general protocols for the administration of chemotherapeutics, taking into account the toxicity, if any, of the vector. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, can be applied in combination with the described hyperproliferative cell therapy.

Inhibitors of Cellular Proliferation

15 The tumor suppressor oncogenes function to inhibit excessive cellular proliferation. The inactivation of these genes destroys their inhibitory activity, resulting in unregulated proliferation. The tumor suppressors p53, p16 and C-CAM are specific embodiments utilized in the present invention. Other genes that can be employed according to the present invention include Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I, 20 MEN-II, zac1, p73, VHL, MMAC1 / PTEN, DBCCR-1, FCC, rsk-3, p27, p27/p16 fusions, p21/p27 fusions, anti-thrombotic genes (e.g., COX-1, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb, fms, trk, ret, gsp, hst, abl, E1A, p300, genes involved in angiogenesis (e.g., VEGF, FGF, thrombospondin, BAI-1, GDAIF, or their receptors) and MCC.

Regulators of Programmed Cell Death

Apoptosis, or programmed cell death, is an essential process for normal embryonic development, maintaining homeostasis in adult tissues, and suppressing carcinogenesis (Kerr et al., 1972). The Bcl-2 family of proteins and ICE-like proteases have been demonstrated to be important regulators and effectors of apoptosis in other systems. The Bcl-2 protein, discovered in association with follicular lymphoma, plays a prominent role in controlling apoptosis and enhancing cell survival in response to diverse apoptotic stimuli (Bakhshi et al., 1985; Cleary and Sklar, 1985; Cleary et al., 1986; Tsujimoto et al., 1985; Tsujimoto and Croce, 1986). The evolutionarily conserved Bcl-2 protein now is recognized to be a member of a family of related proteins, which can be categorized as death agonists or death antagonists. Different family members have been shown to either possess similar functions to Bcl-2 (e.g., BclXL, BclW, BclS, Mcl-1, A1, Bfl-1) or counteract Bcl-2 function and promote cell death (e.g., Bax, Bak, Bik, Bim, Bid, Bad, Harakiri).

Other agents

It is contemplated that other agents can be used in combination with the present invention to improve the therapeutic efficacy of treatment. These additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, or agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers.

Dosage and Formulation

The amino acid sequences and nucleic acid sequences (active ingredients) of this invention can be formulated and administered to treat a variety of disease states by any means that produces contact of the active ingredient with the agent's site of action in the body of an animal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, or with a pharmaceutically acceptable carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will be a therapeutically effective amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired.

The active ingredient can be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions. The active ingredient can also be formulated for administration parenterally by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption. The agent can be administered intramuscularly, intravenously, or as a suppository. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field.

Additionally, standard pharmaceutical methods can be employed to control the duration of action. These are well known in the art and include control release preparations and can include appropriate macromolecules, for example polymers, polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methyl
5 cellulose, carboxymethyl cellulose or protamine sulfate. The concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release. Additionally, the agent can be incorporated into particles of polymeric materials such as polyesters, polyamino acids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also
10 be used to trap the compound in microcapsules.

Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.

Capsules: Capsules are prepared by filling standard two-piece hard gelatin capsules each with a therapeutically effective amount of powdered active ingredient,
15 175 milligrams of lactose, 24 milligrams of talc and 6 milligrams magnesium stearate.

Soft Gelatin Capsules: A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing a therapeutically effective amount of the active ingredient. The capsules are then washed and dried.

20 Tablets: Tablets are prepared by conventional procedures so that the dosage unit is a therapeutically effective amount of active ingredient. 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline

cellulose, 11 milligrams of cornstarch and 98.8 milligrams of lactose. Appropriate coatings can be applied to increase palatability or to delay absorption.

Injectable: A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

Suspension: An aqueous suspension is prepared for oral administration so that each 5 millimeters contain a therapeutically effective amount of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution U.S.P. and 0.025 millimeters of vanillin.

Accordingly, the pharmaceutical composition of the present invention can be delivered via various routes and to various sites in an animal body to achieve a particular effect (see, e.g., Rosenfeld et al. (1991), supra; Rosenfeld et al., Clin. Res., 39(2), 311A (1991a); Jaffe et al., supra; Berkner, supra). One skilled in the art will recognize that although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, peritoneal, subcutaneous, intradermal, as well as topical administration.

The composition of the present invention can be provided in unit dosage form wherein each dosage unit, e.g., a teaspoonful, tablet, solution, or suppository, contains a predetermined amount of the composition, alone or in appropriate combination with other active agents. The term "unit dosage form" as used herein refers to physically

discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the compositions of the present invention, alone or in combination with other active agents, calculated in an amount sufficient to produce the desired effect, in association with a pharmaceutically acceptable diluent, carrier, or
5 vehicle, where appropriate. The specifications for the unit dosage forms of the present invention depend on the particular effect to be achieved and the particular pharmacodynamics associated with the pharmaceutical composition in the particular host.

These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan.
10 Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

The following examples are offered by way of example, and are not intended to
15 limit the scope of the invention in any manner.

EXAMPLE 1

Mouse *atonal* homolog 1 (*Math1*)

It has been found that the present methods for the treatment of the hearing
20 impaired have failed to address the problem directly, that is, the regeneration of auditory hair cell populations. The present invention in a preferred embodiment is directed to a member of the bHLH family, the *Math1* gene or an another *atonal*-associated nucleic acid sequence, and its requirement for generation of cerebellar granule neurons and inner

ear hair cells. This discovery has wide ramifications not only for understanding neurodevelopment but also for therapies for a variety of prevalent disorders, as described below.

The mouse *atonal* homolog 1 (*Math1*) is expressed in the precursors of the cerebellar granule neurons; a few cells in the dorsal portion of the developing spinal cord; the inner ear; Merkel cells (touch receptors on the skins); and joints. Overexpressing *Math1* in an otherwise differentiated cell can induce the formation or differentiation into a progenitor or mature inner ear hair cell-like cell.

Math1 expression in the precursors of the cerebellar granule neurons suggests it is required for function in the cerebellum and brain. The cerebellum is essential for fine motor coordination and posture, and its dysfunction disrupts balance, speech and limb movements. Cerebellar development typically begins at about embryonic day 9.5 (E9.5) when a small group of cells in the hindbrain proliferates and migrates rostrally to form the external granule layer, brain stem, and pontine neurons. This population of neuronal progenitors, which continues to express *Math1*, further proliferates and migrates internally to form the cerebellar granule neurons that are the predominant neuronal population in the cerebellum and brain. Mice that do not express *Math1* completely lack cerebellar granule neurons and their precursors. *Math1* is thus essential for the generation of these neurons and endows the very sparse population of neurons at E9.5 with the ability to proliferate into billions and then differentiate (Ben-Arie et al., 1997). Both these functions are of great medical significance. To understand normal proliferation provides necessary insight into abnormal proliferation, as observed in cancer. Cerebellar tumors of the primitive neuroectodermal type (e.g., medulloblastoma)

are the most common solid malignancy in children. *Math1* expressing cells contribute significantly to these tumors.

Math1 is expressed in the non-ossified joint cartilage (see Figure 6) that typically degenerates in osteoarthritis. This is the most prevalent form of arthritis, with 90% of people over 40 showing some degree of osteoarthritis in one or more joints. Given the properties of *Math1* in cellular generation and proliferation, its artificial expression in affected joints can allow regeneration of the cells that constitute non-ossified cartilage.

Disclosed herein are compositions and methods for the use of the *Math1* gene, its human homolog (*Hath1*) or any of its homologs, orthologs, chimeric fusion proteins or derivatives of any suitable *atonal*-associated nucleic acid sequence or any another *atonal*-associated nucleic acid sequence. To learn about the functions of *Math1* in mammals, the *Math1* gene was deleted from a mouse using a strategy that permitted detection of cells that express *Math1*. Disclosed are the creation and characterization of mice that can be used to screen for compounds which could be utilized to decrease or augment *Math1* expression in inner ear hair cells and other cells in which *Math1* expression is associated.

Methods are also disclosed for the study, characterization and treatment of neoplastic proliferation of neuroectodermal origin since *Math1* expression is essential for the generation and proliferation of cerebellar granule neurons. Also, it has been discovered that *Math1* plays a role in the development of cells that produce non-ossified joint cartilage, which are associated with the development of osteoarthritis. These discoveries have led to a method of screening for compounds that can be helpful for the

treatment of inner ear hair cell loss and other diseases that occur due to the functional loss of *Math1*, such as osteoarthritis.

More particularly, the present invention also provides an animal heterozygous for *Math1* gene inactivation or an another *atonal*-associated nucleic acid sequence, wherein
5 at least one *Math1* allele or another *atonal*-associated nucleic acid sequence has been replaced by insertion of a heterologous nucleic acid sequence, wherein the inactivation of the *Math1* or *atonal*-associated sequence prevents expression of the *Math1* or *atonal*-associated allele. The mouse can be further used to generate mice homozygous for *Math1* or another *atonal*-associated sequence gene inactivation and can further include
10 a second heterologous nucleic acid sequence, wherein at least one of the heterologous genes is used to detect expression driven by the *Math1* or *atonal*-associated sequence regulatory elements. The complete or partial inactivation of the functional *Math1* or *atonal*-associated sequence can be detected in, e.g., proprioceptive cells, granule neurons and their progenitor cells, or non-ossified cartilage cells.

15 Examples of heterologous nucleic acid sequences are reporter sequences such as b-galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase, b-glucuronidase and chloramphenicol transferase (CAT). The *Math1* or *atonal*-associated sequence can also be replaced under the control of regulatable promoter sequences or can be a tissue-specific promoter sequences. Said
20 promoter sequences can be partial or can contain the entire promoter.

The present invention can also be used as, or as part of, a method for screening for a compound, wherein the administration of the compound affects a developmental and/or pathological condition wherein said condition is a result of reduction in expression

of the *Math1* or *atonal*-associated sequence, the method including, administering the compound to a transgenic mouse that is homozygous for *Math1* or *atonal*-associated sequence inactivation, wherein at least one *Math1* or *atonal*-associated allele is inactivated by insertion of a heterologous nucleic acid sequence, wherein the inactivation
5 of the *Math1* or *atonal*-associated sequence prevents expression of the *Math1* or *atonal*-associated gene, and monitoring the mouse for a change in the developmental and/or pathological condition. The types of pathological conditions that can be examined include, but are not limited to loss of hair cells, loss of cerebellar granule neurons or their precursors, lack of granule cell proliferation or migration, lack of cerebellar external
10 granule layer cells, hearing impairment, an imbalance disorder, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation of medulloblastoma. As used herein, the screen provides for a compound that by upregulating expression of a heterologous nucleic acid sequence is a positive effector and for a compound that by downregulating expression of a heterologous nucleic acid
15 sequence is a negative effector.

Yet another embodiment of the present invention is a method of promoting mechanoreceptive cell growth, that includes contacting a cell with a *Math1* or *atonal*-associated protein or gene in an amount effective to cause said cell to express an inner ear hair cell marker. An example of a hair cell marker for use with the method is
20 calretinin. The cell can be contacted with a vector that expresses a *Math1* or *atonal*-associated nucleic acid sequence or amino acid sequence. *Math1* or *atonal*-associated nucleic acid sequence-expressing recombinant vectors can include an adenoviral vector, a retroviral vector, an adeno-associated vector, a plasmid, a liposome, a protein, a lipid,

a carbohydrate and a combination thereof of said vectors. *Math1* or *atonal*-associated sequence can be under the control of, e.g., a cytomegalovirus IE promoter sequence or the cytomegalovirus IE promoter sequence and a SV40 early polyadenylation signal sequence, or any other combination of appropriate promoter sequences, enhancer
5 sequence, and polyadenylation.

Furthermore, a method is disclosed for treating hearing impairment or an imbalance disorder that includes administering to an animal, including a human, with hearing loss or an imbalance disorder a therapeutically effective amount of a *Math1* or *atonal*-associated amino acid sequence or nucleic acid sequence. The hearing or balance
10 impairment can be complete or partial and can affect either one ear or both ears. In a preferred embodiment, there is a substantial impairment of hearing. Hearing and an imbalance disorder can be affected separately or concomitantly in an animal to be treated, and said hearing and/or an imbalance disorder could be as a result of trauma, disease, age-related condition, or could be due to loss of hair cells for any reason.

15 The present invention is also directed to a composition that includes a *Math1* or *atonal*-associated protein or gene in combination with a delivery vehicle, wherein the delivery vehicle causes a therapeutically effective amount of *Math1* or *atonal*-associated sequence to be delivered into a cell. The delivery vehicle can be further defined as a vector that comprises a *Math1* or *atonal*-associated amino acid sequence or nucleic acid
20 sequence in an animal cell. The vector can be a retroviral or an adenoviral vector or any other nucleic acid based vector which can even be dispersed in a pharmacologically acceptable formulation, and used for intralesional administration. The composition can even be a partially or fully purified protein that is delivered using a liposome, a protein,

a lipid or a carbohydrate that promotes the entry of a *Math1* or *atonal*-associated protein into a cell. Examples of proteins that can be used as delivery vehicles include the receptor-binding domains (the non-catalytic regions) of bacterial toxins, such as, e.g., Exotoxin A, cholera toxin and Ricin toxin or protein transduction domains, such as from the HIV TAT protein (Schwarze et al., 1999) (see Example 22). The composition for delivering *Math1* can be a fusion protein.

A skilled artisan is aware that methods to treat animals as disclosed in the invention can be either *in utero* or after birth. Treatment can be given to an embryo and can occur either *ex vivo* or *in vivo*.

EXAMPLE 2

Animal Model for Organogenesis

An effective animal model for deficiency in a gene that controls organogenesis will most often have both alleles stably inactivated so that, throughout embryogenesis, one or more tissues cannot revert to a functional wild-type allele. One method of generating animals with an altered genotype is gene targeting (Mansour et al., 1993), in which homologous recombination of newly introduced DNA sequence (i.e., the targeting sequence or construct) and a specific targeted DNA sequence residing in the chromosome results in the insertion of a portion of the newly introduced DNA sequence into the targeted chromosomal DNA sequence. This method is capable of generating animals of any desired genotype, and is especially useful for gene disruption (i.e., to "knock out") at a specific chromosomal gene sequence by inserting a selectable marker into the gene or completely replacing the gene with another nucleotide sequence.

To knock out a genomic sequence, a cloned fragment must be available and intron-exon boundaries within the fragment defined (Mansour et al., 1993). Typically, the targeting construct contains a selectable marker such as Neo (neomycin resistance, see Mansour et al., 1993) flanked by sequences homologous to the chromosomal target DNA, and beyond one of these flanking sequences the herpes simplex virus thymidine kinase gene (HSV-TK, see generally, McKnight et al., 1980). The targeting construct is introduced, e.g., by electroporation, into embryo-derived stem (ES) cells where homologous recombination results in an insertion of the Neomycin resistance marker (Neo), but not the HSV-TK gene, into the targeted chromosomal DNA sequence. The altered ES cells are neomycin resistant and HSV-TK⁻ and so are able to grow in the presence of both G418 and gancyclovir antibiotics. Random insertions contain the HSV-TK gene and are thus sensitive to gancyclovir (Mansour, et al.). Positive ES clones are then microinjected into blastocysts to generate germ-line chimeric mice, which are then bred to obtain progeny that are homozygous for the knock out gene. Such general methods of generating knock out animals have been demonstrated using mice. Genes in other animals such as rats, guinea pigs, gerbils, hamsters, and rabbits, can also be used as long as sufficient DNA sequence data are available to make an appropriate targeting construct to knock out the gene of interest.

Although *ato* and *Math1* share a high degree of sequence conservation, there was an apparent discrepancy between their expression patterns and the consequences of their loss of function. Whereas *ato* is expressed primarily in the PNS of the fly and its absence causes loss of almost all CHOs (Jarman et al., 1993), *Math1* is expressed in the CNS and

its loss leads to absence of cerebellar granule neurons, the largest neuronal population in the CNS (Ben-Arie et al., 1997). To better understand the functional relations between *ato* and *Math1*, the present invention describes generation of a second *Math1* null allele in mice (*Math1*^{b-gal/b-gal}) by replacement of the *Math1* coding region with a b-galactosidase gene (*lacZ*) and performing a subsequent search for CNS expression of *ato* in the fruit fly. The Examples describe a functional link between *ato* and *Math1*: *ato* is expressed in the fly brain, and *lacZ* expression under the control of *Math1* regulatory elements (*Math1/lacZ*) not only replicated the known expression pattern in the CNS (i.e., the neural tube, spinal cord and cerebellum), but appeared in many other cells of the murine PNS. Overexpression of *Math1* in *Drosophila* caused ectopic CHO formation, providing further evidence that *ato* and *Math1* are functionally conserved.

The connections and consistency of the relationship between *atonal* in *Drosophila* and *Math1* in the mouse suggests that their use as model systems in the art is justified. A family of homologues have been cloned and analyzed in the mouse including MATH1,2,3,4A, 4B, 4C and 5 (Azakawa et al., 1995; Bartholoma and Nave, 1994; Ben-Arie et al., 1997; Ben-Arie et al., 1996, Fode et al., 1998; Ma et al., 1998; McCormick et al., 1996; Shimizu et al., 1995; Takebayashi et al., 1997). It has been suggested that *Math1* and *Math5* are the only true *ato* homologues given their amino acid sequence criteria, sharing 67% and 71% identity with the bHLH domain of ATO, respectively (Ben-Arie et al., 2000). A *Xenopus atonal* homolog, *Xath1* has been ectopically expressed in *Drosophila* and shown to behave similarly to *ato* (Kim et al., 1997). Furthermore, the ability of *Math1* to induce ectopic CHO formation and to restore CHOs to *ato* mutant embryos (see Example 13) is strong evidence that *Math1*, and particularly

its basic domain, encodes lineage identity information not unlike that encoded by *ato* and that mammalian cells expressing *Math1* are functionally similar and perhaps evolutionarily related to *Drosophila* cells that require *ato*. Thus, the similarities between *atonal* in *Drosophila*, *Xath1* in *Xenopus* and *Math1* in the mouse indicate that these animals are comparable animal model systems. Furthermore, the widespread use of mice in particular as a model system for humans also suggests that it similarly would allow utilization of the invention in humans.

With advances in molecular genetics now standard in the art, sequences from humans and other species can be used interchangeably in a variety of organisms. For example, the rat inducible *hsp70* gene was used to produce transgenic mice that overexpressed inducible *hsp70*, allowing organs from transgenic mice to be protected from ischemic injury (Marber et al. *J. clin. Invest.* 95:1446-1456 (1995)) due to the increase in rat *hsp70*. Sequences in other animals have been interchanged including between humans and rodents to develop rodent models to study human disease, i.e. neurodegenerative diseases. One such example is the expression of the human *SCA1* gene, which encodes ataxin-1, in mice (Burright, E. N. et al. *Cell* 82:937-948 (1995)). Transgenic mice were generated expressing the human *SCA1* gene with either a normal or an expanded CAG tract. The data illustrated that the expanded CAG repeats were expressed in sufficient amounts in the Purkinje cells to produce degeneration and ataxia. This example illustrates that a mouse model can be established to study spinocerebellar ataxia type 1, which is an autosomal dominant inherited neurologic disorder. In addition to developing mouse models, *Drosophila* is a hallmark model system in the field. Warrick et al. (1999) produced transgenic flies which co-expressed human *hsp70* and a

human mutant polyglutamine (*MJDtr-Q78*). Expression of the human mutant polyglutamine *MJDtr-Q78* alone in the flies resulted in the formation of large aggregates in neurons. However, co-expression with human *hsp 70* resulted in suppressed aggregation. These examples illustrate that interchangeability of genes is routine in the field of molecular genetics and model systems provide powerful tools to characterize gene function.

EXAMPLE 3

Generation of Transgenic *Math1* Mice

To detect subtle *Math1* expression patterns not identified by RNA *in situ* hybridization, and thus further illuminate this gene's role during embryonic development, *Math1* null alleles (*Math1* ^{β -Gal/ β -Gal}) were generated by replacing the *Math1* coding region with β -galactosidase (β -Gal).

The targeting construct, containing a *lacZ* cassette and a *PGK-neo* cassette (Fig. 7A), was used to replace the *Math1* coding region. To delete the entire coding region of *Math1*, a targeting construct was generated that contained the 5' and 3' genomic flanking fragments as described previously (Ben-Arie et al., 1997) flanking a pSAbgal/PGK-neo cassette (Friedrich and Soriano, 1991). The construct is designed so that *lacZ* expression is driven by endogenous *Math1* control elements, while an independent PGK promoter drives the expression of the selectable marker *neo*.

The construct was electroporated into ES cells and selection for *neo* was achieved with G418. Fourteen out of 76 (18%) clones underwent homologous recombination. Genotyping of ES cells, yolk sac and tail DNA was performed using Southern analysis

of *EcoR* I digested DNA and probes previously described (Ben-Arie et al., 1997). The targeting construct was electroporated into embryonic stem (ES) cells; 14/76 (18%) clones exhibited correct homologous recombination at the *Math1* locus (Fig. 7B).

Three ES cell lines carrying the *Math1*^{+b-gal} allele were injected into host
5 blastocysts to generate chimeric mice. *Math1*^{+b-gal} mice were identified and intercrossed to generate homozygotes (Fig. 7C). The *Math1* deletion was confirmed by Southern analysis using both flanking and internal probes (Fig. 7A).

Math1^{β-Gal/β-Gal} mice show all the phenotypic features reported in the *Math1*^{-/-} mice (Ben-Arie et al., 1997; 2000).

10

EXAMPLE 4

X-gal staining, histological and immunohistochemical analyses

Embryos were staged by vaginal plug, with the morning of the plug designated E0.5. Embryos were dissected out of the uterus, separated from extraembryonic
15 membranes, and placed in cold phosphate buffered saline (PBS). The embryos were then fixed in 4% paraformaldehyde (PFA) in PBS for 30 minutes, and washed in cold PBS. Yolk sacs or tails were collected before fixation for DNA extraction and genotyping. Equilibration to improve the penetrability of the staining reagents was performed in 0.02% NP40, 0.01% sodium deoxycholate in PBS for 10 minutes at room temperature.
20 Whole mount staining with X-gal (Bonnerot and Nicolas, 1993) was performed for 16-24 hours at 30°C while shaking in the same equilibration buffer, which also contained 5mM potassium ferricyanide, 5mM potassium ferrocyanide, and 40 mg/ml X-gal (dissolved in DMSO). When the desired intensity of staining was achieved, usually within 18 hours,

embryos were washed in PBS, postfixed for 30 minutes in buffered formalin, serially dehydrated in 25, 50, and 70% ethanol, and stored at 4°C.

For histological analysis embryos were further dehydrated in 80, 90, and 100% ethanol, treated in HistoClear (National Diagnostics), and embedded in Paraplast (Oxford Labware). Seven to 20 µm sections were cut using in a microtome (Microme). Counterstaining was performed using nuclear fast red (Vector Laboratories). Immunohistochemistry was performed as detailed previously (Ben-Arie et al., 1997). Antibodies: Anti-cytokeratin 18 (DAKO) 1:20; Anti-human Chromogranin A (DAKO) 1:100; Anti-MATH1 (see below) 1:200.

EXAMPLE 5

Expression Patterns in Transgenic *Math1* Mice

As expected, β-Gal expression in the cerebellum and dorsal spinal cord is identical to that of *Math1*, and interestingly, β-Gal is also expressed throughout the otic vesicle epithelia at E12.5 and in the sensory epithelia of the utricle, saccule, semicircular canals, and cochlea at E14.5 and E15.5 (Figures 1A and 1B). Utricles were obtained from C57BL/129SVEV mice.

Gross morphological analysis of the inner ear of *Math1*^{β-Gal/β-Gal} mice at E18.5, one day before full gestation, revealed no obvious defects in overall structure and size compared with wild type (wt) littermates. The branches of the VIIIth cranial nerve were present and reached the epithelia, but degenerated due to absence of the hair cells.

The sensory epithelia were examined in detail. The utricles and cochleas of wild-type, *Math1*^{+ /β-Gal}, and *Math1*^{β-Gal/β-Gal} mice were excised to allow viewing of the sensory

epithelia with Nomarski optics. Hair bundles were present in both organs of wild-type and heterozygotes, but were completely absent in *Math1* null litter-mates. Scanning electron microscopy (SEM) of the cochlea and vestibular organs confirmed the absence of hair bundles in null mice (Figures 2A through 2F). To determine whether lack of hair bundles reflects the absence of hair cells, cross-sections of the sensory epithelia of all inner ear organs using both light and transmission electron microscopy (LM and TEM, respectively) were examined (Figures 3A through 3F). LM and TEM were carried out as described previously (Lysakowski and Goldberg, 1997). Tissue preparation for SEM consisted of osmication (1% OsO₄ in cacodylate buffer), dehydration, critical-point drying, sputter-coating with gold, and examination in a JEOL 35S electron microscope.

Light microscopy revealed that sensory epithelia in null mice are considerably thinner, lack the normal stratification of cell nuclei and stain uniformly, all of which are consistent with the absence of hair cells. TEM clearly distinguishes between hair cells and supporting cells in normal utricles: hair cells have hair bundles, less electron-dense cytoplasm, more apical nuclei, and no secretory granules (Figures 4A and 4B). The sensory epithelia of the null mutants lack hair cells entirely but do have supporting cells with normal appearance (Rüsch, et al.,1998), including electron-dense cytoplasm, basal nuclei, and secretory granules. However heterozygous *Math1*^{+/-b-Gal} mice retain hair cells.

EXAMPLE 6

Expression of a Hair Cell Specific Marker in Transgenic *Math1* Mice

Lack of hair cells at E18.5 can be due to (1) lack of sensory cell progenitors, (2) the inability of progenitors to differentiate into hair cells, or (3) the inability of hair cells

to maintain the differential states, as has been observed in the absence of the POU domain transcription factor *Brn3c*. The first possibility is unlikely because progenitors give rise to both hair cells and supporting cells. To evaluate the remaining possibilities, the expression of the hair cell specific marker, calretinin and myosin VI were examined.

5 Calretinin is a member of the calcium binding family of proteins and is expressed in differentiating hair cells (prior to hair bundle formation) and mature inner ear and auditory hair cells, but not in supporting cells. Calretinin expression in *Math1* ^{β -Gal/ β -Gal} and wild-type mice was studied by immunofluorescence on coronal sections of E15.5, E16.5 and E18.5 embryos (Figures 5A through 5F).

10 For immunofluorescence, embryos were fixed for 1.5 hours in 4% paraformaldehyde/PBS at 4°C, sunk through 15% sucrose/PBS for 5 hours then 30% sucrose/PBS overnight, and snap frozen in a 2-methylbutane dry ice bath. 14 μ m sections were cut on a cryostat and mounted onto gelatin-coated slides. Sections were fixed onto slides by dipping for 10 minutes in Streck tissue fixative (Streck laboratories) and air drying. Sections were blocked in 30% normal goat serum and 0.3% triton X-100 in PBS for 1 hr at room temperature (RT). Rabbit anti-calretinin polyclonal antibody (Chemicon laboratories) was diluted 1:200 in blocking solution and incubated overnight on sections at 4°C. Sections were washed 3 times (20 minutes each) in Phosphate-Buffered Saline (PBS) at RT. The secondary antibody anti-rabbit antibody, Alexa 488
15 (Molecular Probes), was diluted 1:400 in blocking solution and used to detect calretinin. Sections were covered and incubated at RT for 2 hours before washing and mounting in Vectashield containing DAPI (Vector). For confocal microscopy, sections were treated with 25 μ g/ml RNase before counterstaining with 50 μ g/ml of propidium iodide and
20

mounted in Vectashield without DAPI. Stained sections were viewed under a Bio-Rad 1024 confocal microscope.

Calretinin-positive cells are clearly visible in the sensory epithelia of the semicircular canals and utricles of wild-type mice, but *Math1* ^{β -Gal/ β -Gal} embryos lack
5 calretinin expression at all three states. Using the mouse model disclosed herein the present inventors demonstrate that hair cells never develop within the sensory epithelia of *Math1* ^{β -Gal/ β -Gal} mice. The presence of the tectorial and otolithic membranes (secreted in part by the supporting cells), together with the TEM results, suggests that the remaining cells in the sensory epithelia of the *Math1* ^{β -Gal/ β -Gal} mice are functional
10 supporting cells.

EXAMPLE 7

***Math1/lacZ* expression mimics *Math1* expression in the developing CNS**

The developing cerebellum at E14.5 and postnatal day 0 (P0) in *Math1*^{+b-gal} and
15 *Math1*^{b-gal/b-gal} mice were analyzed by RNA *in situ* hybridization analysis.

The analysis showed that the expression pattern of the *lacZ* gene faithfully reproduced the *Math1* expression pattern observed by RNA *in situ* hybridization analysis shown previously (Akazawa et al., 1995; Ben-Arie et al., 1996) (Fig. 2A, B, E, G). Moreover, the cerebellar phenotype in *Math1*^{b-gal/b-gal} mice (Fig. 8F and 8H) was identical
20 to that observed in *Math1* null mice (Ben-Arie et al., 1997). At E14.5, the precursors of the EGL are present in the rhombic lip from which they migrate over the cerebellar anlage to populate the EGL (Fig. 8E). Mutant mice displayed far fewer of these cells

than heterozygous mice (Fig. 8F). At P0, the neurons of the external granule layer (EGL) were completely lacking (Fig. 8H).

Math1/lacZ expression in the developing hind brain and spinal cord similarly reproduced the expression pattern of *Math1* (Fig. 8 C, 8D). The only notable difference between the expression patterns established by *in situ* hybridization and *lacZ* staining is that b-galactosidase expression persists in differentiating or migrating cells of the spinal cord because of the stability of the b-GAL protein (Fig. 8D). In summary, the neural tissue expression pattern and cerebellar phenotype associated with the replacement of the *Math1* coding region by *lacZ* is consistent with previously published data on *Math1* expression (Akazawa et al., 1995; Ben-Arie et al., 1997; Ben-Arie et al., 1996; Helms and Johnson, 1998), demonstrating that the endogenous control elements were not disrupted by insertion of the *lacZ* gene. Moreover, many previously undetected clusters of *lacZ*-expressing cells became apparent upon X-gal staining of whole embryos and sections in *Math1*^{+/-b-gal} mice (see below). It is likely that limitations in the spatial resolution of RNA *in situ* hybridization techniques used to detect the transcript in earlier studies prevented these sites of expression from being discerned (Akazawa et al., 1995; Ben-Arie et al., 1996). Alternatively, the stability of the *lacZ* gene product and the increased sensitivity due to signal amplification allowed us to identify sites of relatively low expression levels.

EXAMPLE 8

***Math1/lacZ* is expressed in inner ear sensory epithelia**

The sensory organs of the inner ear were among the newly identified sites of *Math1/lacZ* expression, demonstrated utilizing the methods described in Example 2. Expression in the otic vesicle was first detected at E12.5 and continued until E18.5 throughout much of the sensory epithelia (Bermingham et al., 1999) (Figure 9A, 9B).
5 Null mutants displayed *Math1/lacZ* expression in the inner ear throughout embryogenesis (Fig. 9C). *Math1* null mutants lack hair cells in all of the sensory organs (Bermingham et al., 1999), but maintain supporting cells, the other sensory epithelia-derived cells (Fig. 9C). These supporting cells seem to be functional, based on their morphology and the presence of overlying membranes secreted in part by these cells. Although the
10 expression of *Math1* in inner ear sensory epithelia was not demonstrated by RNA in situ hybridization analysis, the complete lack of inner ear hair cells in the null mutants leaves little doubt about the authenticity of the *Math1/lacZ* expression pattern.

Math1 is clearly essential for hair cell development in the inner ear. Its expression pattern and *in vivo* function are akin to those of *Math1*'s proneural homolog,
15 *atonal (ato)* (A. P. Jarman, Y. Grau, L. Y. Jan, Y. N. Jan, *Cell* 73, 1307-21 (1994)). *ato* is expressed in a ring of epithelial cells within the antennal disc of *Drosophila*. Some of these epithelial cells will subsequently develop into mechanoreceptors in the Johnston organ, which is necessary for hearing and negative geotaxis. It is interesting to note that mechanoreceptor progenitor cells are absent in *ato* mutants, whereas only the
20 mechanoreceptors, and not their progenitors, are absent in *Math1* null mice.

Based on the observations made herein, the present inventors have recognized that *Math1* is required for the specification of inner ear hair cells. In a sense, *Math1* acts as a "pro-hair cell gene" in the developing sensory epithelia. In conjunction with two recent

studies, the present inventors have recognized that the results provided herein provide evidence supporting a lateral inhibition model for the determination of hair cells and supporting cells (Haddon et al., 1998; Adam, et al., 1998), in which the interplay of *Delta*, *Notch*, and *Serrate1* results in the selection of individual hair cells from clusters of competent cells. Such a model entails that the sensory epithelia express a “pro-hair cell gene” whose function is essential for hair cell fate specification.

The ectopic expression of *ato* in the fruitfly and its homolog *Xath1* in *Xenopus* (Kim et al., 1997) can recruit epithelial cells into specific neuronal fates, and the expression of *Math1* in inner ear epithelia strongly suggests loss of a functional *Math1* gene is likely to be a common cause of deafness and vestibular dysfunction.

EXAMPLE 9

***Math1/lacZ* is expressed in brain stem nuclei**

In the brainstem *Math1/lacZ* staining appeared from E18.5 to P7 in the ventral pons in the regions corresponding to the pontine nuclei (Fig. 9D and inset). This finding is consistent with the hypothesis of Akazawa and colleagues that *Math1*-positive cells in the developing hind brain are precursors to the bulbopontine neurons (Akazawa et al., 1995). No such staining appeared in the null mutants (Fig. 9E and inset). These data raise the possibility that the absence of *lacZ* staining in pontine nuclei can be due to failure of their precursors to migrate, proliferate, and/or differentiate. Ventral pontine nuclei were examined upon haematoxylin and eosin staining of sections and were found to be missing in the brain stem of null mice (Fig. 9F, G). Furthermore, the failure of null mouse newborns to breathe can be due to absence of these brainstem neurons.

EXAMPLE 10

***Math1/lacZ* is expressed in chondrocytes**

Math1^{+/-b-Gal} heterozygotes displayed expression of *Math1* in articular cartilage (Figures 6A and 6B). Figure 6A demonstrates expression in all joints of a forelimb. Upon closer examination of an elbow joint, *Math1* is noted to be expressed exclusively in the non-ossified articular chondrocytes.

Expression of *Math1/lacZ* was detected in the developing proximal joints, such as those of the hip and shoulder, as early as E12.5 (Fig 10A). X-gal positive staining was detected at subsequent developmental stages in a progressive proximal-distal pattern that paralleled the normal development of joints (Figure 10B). In the joints, *Math1/lacZ* expression immediately follows mesenchymal condensation, which begins at E11.5. Condensed mesenchyme cells differentiate into chondrocytes (Bi et al., 1999; Horton et al., 1993; Karsenty, 1998).

Chondrocytes differentiate in three major phases during bone formation: resting, proliferating and hypertrophic. The resting chondrocytes that populate the articular cartilage are referred to as articular chondrocytes (Buckwalter and Mankin, 1998; Poole, 1997). Prior to birth, resting chondrocytes constitute the entire chondrocyte population in joints. To establish which cells expressed *Math1/lacZ*, sections from E18.5 and P7 *Math1*^{+/-b-gal} mice were stained with X-gal. *Math1/lacZ* is expressed in the resting chondrocytes of all joints analyzed at E18.5; resting chondrocytes in the elbow joint are shown in Figure 10C, and Fig. 10D shows the resting, proliferating, and articular chondrocytes of a P7 mouse.

The joints of E18.5 embryos were examined with anti-MATH1 antibody prepared by the following methods. An *EcoR* I-*Hind* III fragment encoding the N-terminal 156 amino acids of the *Math1* open reading frame (*Math1D*) was cloned into the pET 28a+ expression vector (Novagen). *Math1D* fragment was expressed as a His tag fusion protein. Soluble MATH1D protein was purified according to His-tag kit specifications (Novagen) and 2mg of protein were used to immunize Chickens (Cocalico Biologicals Inc.).

Expression was found in resting chondrocytes, whereas no expression was observed in null embryos. It should be noted that not all articular cartilage cells express *Math1/lacZ* (Fig. 10E). *Math1/lacZ* expression in *Math1* null mutants is similar to that in heterozygous mice at E18.5, suggesting that *Math1* is not required for resting chondrocyte development.

EXAMPLE 11

***Math1/lacZ* is expressed in Merkel cells**

By E14.5 *Math1/lacZ*-positive cells were apparent around the vibrissae and in the skin of much of the body (Fig. 10B). In the trunk, the stained cells were arranged in a striped pattern defined by the epidermal ridges. This staining was apparent only in the hairy, not the glabrous, skin. All the primary (mystical) vibrissae, including the lateral nasal, maxillary and four large hairs, were positive for *Math1/lacZ*. Staining was also detected in the secondary vibrissae, including the labial, submental, rhinal, and isolated orbital vibrissae (supra-, infra- and post-orbital) (Yamakado and Yohro, 1979). By E15.5 staining appeared in clusters of cells in the foot pads (Fig. 10B).

To identify the *Math1/lacZ*-positive cells in the vibrissae, footpad, and hairy skin, we examined histological sections from *Math1*^{+/-b-gal} mice (Fig. 11A-D). Sections through the vibrissae showed that the stained cells are localized to the more apical half of the hair shaft, but are not in the hair itself. Cross sections through the foot pad illustrated staining of cluster of cells in the epidermal layer (Fig. 11 B,C). As shown in Fig. 11D, sections through the truncal skin identified clusters of *Math1/lacZ*-stained cells. The stained cells were arranged in a horseshoe-shaped pattern centered within an elevated button-like structure in the hairy skin. These button-like structures were identified as touch domes or Haarscheiben (Pinkus, 1905), which are characterized by a thickened epidermis and an elevated dermal papilla with a capillary network. Touch domes are associated with large guard hairs dispersed between other hair types in the coat. The spatial distribution of *Math1/lacZ*-stained cells, the timing of their appearance at E14.5, and their localization within the mystical pads of the vibrissae and the touch domes in the hairy skin suggest that these cells correspond to Merkel cells, specialized cells in the epidermis that form slow-adapting type I mechanoreceptor complexes with neurites (Munger, 1991).

The results of comparative analysis of the *Math1/lacZ* expression pattern in heterozygous and homozygous E16.5 animals are shown in Figure 11E-L. *Math1*^{b-gal/b-gal} embryos displayed a staining pattern similar to that of *Math1*^{+/-b-gal} littermates in the vibrissae and footpads (Fig.11E-G, I-K). In contrast, staining in the touch domes of the hairy skin was barely detectable in *Math1*^{b-gal/b-gal} embryos (Fig. 11H,L). The reduction of staining in null animals was also obvious at E18.5.

To further define *Math1/lacZ*-positive cells in the skin, *Math1*^{+b-gal} mice were mated to *Tabby* mice. *Tabby* (*Ta*) is a spontaneous X-linked mutation displaying a similar phenotype in hemizygous males and homozygous females (Ferguson et al., 1997). *Tabby* mutants lack hair follicles (tylotrich), a subset of Merkel cells that are associated with touch domes in the hairy skin of the trunk (Vielkind et al., 1995), and some of the five secondary vibrissae on the head (Gruneberg, 1971). Hence, in a cross of *Ta/Ta* females with a heterozygous *Math1*^{+b-gal} male, 50% of the male progeny are *Ta/Y: Math1*^{+b-gal}, allowing us to assess whether the *Math1/lacZ*-positive cells correspond to Merkel cells.

Ta/Ta females were time-mated with *Math1*^{+b-gal} males, and embryos were harvested at E16.5. Each pup's gender was determined by PCR on tail DNA, using primers (forward 5'-TGAAGCTTTTGGCTTTGAG-3'; SEQ ID NO:67, and reverse 5'- CCGCTGCCAAATTCTTTGG-3'; SEQ ID NO:68) that yielded a 320 bp product from chromosome X, and a 300 bp product from chromosome Y (Liu et al., 1999). Amplification conditions were: 92°C/1 min, 55°C/1 min, 72°C/1 min for 32 cycles, with an initial denaturation step of 94°C/7 min and last extension step of 72°C/7 min. Amplification products were separated on 2% agarose gels. X-gal-stained embryos were scored independently by 2 individuals, and only then were results matched with the determined gender.

Both *Tabby* females and males carrying the *Math1*^{+b-gal} allele displayed X-gal staining in the vibrissae and foot pads (Fig. 12A,B). The effect of the *Tabby* mutation on the number of secondary vibrissae was quite clear: hemizygous males completely lacked *Math1/lacZ*-positive cells in the secondary vibrissae (typically lacking in *Ta*

mutants) and on the trunk (Fig. 12E). Females that are heterozygous for *Tabby* showed patchy staining in the touch domes (although less than wt), as should be anticipated in female carriers of a mutation in a gene that undergoes random X chromosome inactivation (Fig. 12C,D). The localization and distribution of the positive cells, as well as their absence in selected vibrissae and the trunk of *Tabby* males, strongly indicate that *Math1* is expressed in the Merkel cells associated with guard follicles in the touch domes of the hairy skin.

To ascertain whether *Math1/lacZ* staining pattern reflects normal *Math1* expression pattern, immunohistochemical analysis of MATH1 was performed on sections from abdominal skin (see Example 2). As seen in Fig. 13A and B, MATH1-positive cells were detected around the hair follicles of *Math1*^{+/+} but not *Math1*^{b-gal/b-gal} mice. Antibodies against two Merkel cells markers were chosen for further analysis: anti-cytokeratin18, expressed in simple epithelia, and chromogranin, localized to secretory granules of neuroendocrine, endocrine, and neuronal tissues. Both cytokeratin 18 (Fig. 13C,D) and chromogranin A (Fig. 13E,F) confirmed the identity of the *Math1/lacZ*-positive cells as Merkel cells, but did not reveal staining abnormalities in *Math1*^{b-gal/b-gal} mice. Thus, *Math1* does not seem to be essential for the genesis of the neuroendocrine Merkel cells, in contrast to pure neuronal cell types like cerebellar EGL and pontine nuclei. Because *Math1* null mutants die at birth, we can not assess whether the entire cluster of Merkel cells is formed or the functional integrity of Merkel cells in these mutants is affected.

EXAMPLE 12

***Math1* partially rescues Chinese Hamster Ovary Cells**

(CHO) in flies deleted for *ato*

This Example demonstrates that *atonal*-associated genes can induce the development of CNS cells in animals deficient in a native *atonal*-associated gene or gene product. This Example also demonstrates that *atonal*-associated genes can therapeutically function in species in which they are not natively expressed.

Given the remarkable similarity in expression patterns of *ato* and *Math1*, and their identical basic domains, *Math1* was tested to see if it would mimic the effects of *ato* overexpression by producing ectopic chordotonal organs as described by the following methods. Wild-type, also known as *yw* flies, were transformed with a *UAS-Math1* construct as described (Brand and Perrimon, 1993). To overexpress *Math1* in wild type flies, *yw; UAS-Math1* flies were mated to *HS-Gal4* flies. The progeny were heat shocked as previously described (Jarman et al., 1993). To rescue the loss of chordotonal organs in *ato* mutant flies, *w; UAS-Math1/UAS-Math1; ato1/TM6* flies were crossed to *w; HS-Gal4/CyO; ato1/TM6* flies. Embryos were collected for 3 hr., aged for 3 hr., heat shocked for 30 min. at 37°C and allowed to develop for the next 12-15 hr. Embryos were fixed in 4% formaldehyde in PBS with 50% heptane. Embryos were washed with 100% ethanol, transferred to PBT and stained with mAb 22C10 as previously described (Kania et al., 1995) to detect PNS neurons. Chordotonal neurons were identified by their distinct morphology and position.

Expressing *Math1* during pupal development by heat shock using the UAS-Gal4 system (Brand and Perrimon, 1993) resulted in supernumerary external sense organs on the notum (Fig. 14A,B) and the wing blade, as reported for *ato* (Jarman et al., 1993) and

the *Achaete-Scute complex* (*AS-C*) genes (Brand and Perrimon, 1993; Rodriguez et al., 1990). *Math1* expression in flies, like *ato*, produced ectopic chordotonal organs (Fig. 8G), although with less efficiency. Overexpression of the *AS-C* genes does not, however, result in ectopic chordotonal organs (Jarman et al., 1993). *Math1* thus has a similar functional specificity to *ato*.

Since several *ato* enhancers are *ato*-dependent (Sun et al., 1998), they can be activated by *Math1*, which would then lead to ectopic CHO specification. To determine whether *Math1* can substitute for *ato* function in the fly, and to rule out the possibility that production of CHOs by *Math1* is due to *ato* activation, *Math1* was expressed in *ato* mutant embryos. The mutants lack all chordotonal neurons (Fig. 14C), but overexpressing *Math1* partially rescues the loss of these neurons (Fig. 14D) in a manner similar to *ato* (Chien et al., 1996).

EXAMPLE 13

Significance of *atonal* and *Math1* in the CNS and PNS

Over the past few years significant progress has been made towards unraveling the roles of bHLH proteins in vertebrate neurogenesis. Neural vertebrate bHLH-encoding genes were isolated and characterized because *Drosophila* homologues such as *ato* or the *AS-C* genes had been previously shown to be required for neurogenesis (Anderson, 1995; Guillemot, 1995; Lee, 1997; Takebayashi et al., 1997). Indeed, several genes were shown to be proneural because their absence caused a failure of neuroblast or sensory organ precursor (SOP) specification, whereas their overexpression lead to the recruitment

of supernumerary neuronal precursors (Ghysen and Dambly-Chaudiere, 1989). With the exception of *neurogenin (Ngn) 1* and *2* (Fode et al., 1998; Ma et al., 1998), it remains uncertain which of the vertebrate homologues play roles similar to their *Drosophila* counterparts, and what precise role different bHLH proteins play in neural development.

5 In *Drosophila*, *ato* is required for the development of a specific subset of sense organs, the chordotonal organs (Jarman et al., 1993). CHOs are internal mechanosensors of the PNS (McIver, 1985). Thus, *ato* and the CHOs provide an excellent system in which to ascertain not only the molecular and developmental relationship between invertebrate and vertebrate neurogenesis vis-à-vis the function of the proneural genes, but also the

10 evolutionary conservation of sensory organ function and specification. Seven *ato* homologues have been cloned and analyzed in the mouse: *Mouse Atonal Homologues (MATH) 1, 2, 3, 4A* (also known as *Ngn2*), *4B (Ngn3)*, *4C (Ngn1)*, and *5* (Akazawa et al., 1995; Bartholomä and Nave, 1994; Ben-Arie et al., 1997, 1996; Fode et al., 1998; Ma et al., 1998; McCormick et al., 1996; Shimizu et al., 1995; Takebayashi et al., 1997). Most

15 are expressed during neurogenesis in both the CNS and PNS. These homologues vary in the degree of their sequence conservation, and can be divided into three groups. The most distantly related group, the neurogenins, includes *Ngn 1, 2* and *3*. These gene products share, on average, 53% identity in the bHLH domain with ATO. They are expressed largely in mitotic CNS and sensory ganglia progenitor cells. Recent work suggests that

20 these genes can play a role in neuroblast determination, and can therefore be true proneural genes (Fode et al., 1998; Ma et al., 1998). The second group includes MATH2 and MATH3, which share 57% identity in the bHLH domain with ATO. These proteins have been postulated to function in postmitotic neural cells (Bartholomä and Nave, 1994;

Shimizu et al., 1995). *Math2* expression is confined to the CNS, while *Math3* is expressed in both the CNS and the trigeminal and dorsal root ganglia. The third group includes MATH1 and MATH5, arguably the only true *ato* homologues by amino acid sequence criteria, sharing 67% and 71% identity with the bHLH domain of ATO, respectively. It is noteworthy that both genes encode a basic domain identical to that of ATO. Interestingly, the basic domain of ATO was shown to be sufficient, in the context of another proneural protein (SCUTE), to substitute for the loss of *ato* function (Chien et al., 1996). *Math1* was initially shown to be expressed in the precursors of the cerebellar EGL and in the dorsal spinal cord (Ben-Arie et al., 1997, 1996). *Math5* is expressed in the dividing progenitors in the developing retina and in the vagal ganglion (Brown et al., 1998). With the exception of *Math5* expression in the neural retina, these observations pose a paradox: none of the vertebrate homologs appeared to be expressed in peripheral organs or tissues similar to those where *ato* is expressed. Jarman et al. (1993) reported that *ato* is expressed in the CNS. In the examples described herein it is shown that, in addition to the inner proliferation center of the optic lobe, *ato* is expressed in a small anteriomedial patch of cells in each brain lobe (Fig. 8F). Because it remains unclear, however, precisely what role *ato* plays in Drosophila CNS development, it has been difficult to argue that *ato* and its vertebrate homologues display functional conservation. Our experiments reveal sites of previously uncharacterized *Math1* expression. As expected, we found that *Math1/lacZ* expression in the CNS corresponds to that of *Math1*, but we also found that *Math1* is expressed in the skin, the joints, and the inner ear, in striking parallel to *ato* expression in the fly. Moreover, the expression in the ear (sensory epithelium) and the skin (Merkel cells) is restricted to sensory structures whose function

is to convert mechanical stimuli into neuronal electrochemical signals. It is important to point out that in *Drosophila*, *ato* appears to play two roles simultaneously. It is required not only to select the precursors of the CHOs (proneural role), but also to specify these precursors as CHO precursors (lineage identity role) (Jarman and Ahmed, 1998; Jarman et al., 1993). The specificity of *Math1* expression in the periphery makes it tempting to speculate that it, too, can endow specific cells with very specific lineage identities to distinguish them functionally from other sensory structures. The ability of *Math1* to induce ectopic CHO formation and to restore CHOs to *ato* mutant embryos supports the notion that *Math1*, and particularly its basic domain, encodes lineage identity information not unlike that encoded by *ato*. This suggests that the mammalian cells expressing *Math1*, at least in the ear and the skin, are functionally similar and perhaps evolutionarily related to *Drosophila* cells that require *ato*. Furthermore, *Math5* expression in the neural retina suggests that the functions of *atonal* in the fly are carried out by two genes in the mouse: the development of some mechanoreceptors is under the control of *Math1* and retinal development is possibly under the control of *Math5*. It is interesting to note that in the fully sequenced nematode *C.elegans*, only one homolog of *atonal*, *lin-32*, was identified (Zhao and Emmons, 1995). Mutants with the u282 allele of *lin-32* are touch-insensitive, which strengthens the argument for evolutionary conservation of *atonal* function in mechanoreception. The pattern of *Math1/lacZ* expression in the pontine nuclei suggested this region should be carefully evaluated in null mutants. Although no defects in the pons of *Math1* null mice (Ben-Arie et al., 1997) were originally detected, closer analysis revealed the lack of pontine nuclei at this site. These neurons derive from the rhombic lip (Altman and Bayer, 1996) as do the EGL neurons, which are also lacking in *Math1* null

mice. While it is possible to draw parallels between *Math1* and *ato* expression in the skin and ear, it is not clear that such is the case for the joints. *ato* expression in the fly joints is required for the formation of leg CHOs. In contrast, *Math1* is expressed in resting and articular chondrocytes that do not have any described neural function, and for which no
5 parallels exist in the fly. It can be that *Math1* expression in cartilage indicates a novel role for a mechanosensory gene, or it can simply reflect similarities in the molecular events underlying the development of the various *Math1*-expressing cell types. Alternatively, CHOs can also function as joint structural elements in the fly, or articular cartilage can have a mechanoreceptive or transductive capacity yet to be described. There is no
10 evidence at this point to support one or another of these possibilities. Analyzing the functions of *ato* and *Math1* will enhance our understanding of neural development and the evolutionary conservation of sensory function. The sites and specificity of *Math1* expression can make it suitable as a tool of gene therapy or gene activation approaches to illnesses such as hearing loss and osteoarthritis that are due to age-related or
15 environmental damage.

EXAMPLE 14

***Atonal*-Associated Nucleic Acid Delivery using Adenovirus**

20 Human adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kb. As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system. This group of viruses is easy

to grow and manipulate and they exhibit a broad host range *in vitro* and *in vivo*. In lytically infected cells, adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus.

5 The E1 region of the genome includes E1A and E1B, which encode proteins responsible for transcription regulation of the viral genome, as well as a few cellular genes. E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, *e.g.* DNA-binding protein, DNA polymerase, and a terminal protein that primes replication. E3 gene products prevent cytolysis by cytotoxic T cells and tumor
10 necrosis factor and appear to be important for viral propagation. Functions associated with the E4 proteins include DNA replication, late gene expression, and host cell shutoff. The late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred. The major late promoter (MLP) exhibits high efficiency during
15 the late phase of the infection.

 As only a small portion of the viral genome appears to be required *in cis*, adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells. Ad5-transformed human embryonic kidney cell lines have been developed to provide the essential viral
20 proteins *in trans*. The inventors thus reasoned that the characteristics of adenoviruses rendered them good candidates for use in targeting *Math1* deficient cells *in vivo*. In another embodiment these constructs include a *Hath1* or any *atonal*-associated nucleic acid sequence.

Particular advantages of an adenovirus system for delivering foreign proteins to a cell include: (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA; (ii) the structural stability of recombinant adenoviruses; (iii) the safety of adenoviral administration to humans; (iv) lack of any known association of adenoviral infection with cancer or malignancies; (v) the ability to obtain high titers of the recombinant virus; and (vi) the high infectivity of Adenovirus.

One advantage of adenovirus vectors over retroviruses is a higher level of gene expression. Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences. Because adenovirus transforming genes in the E1 region can be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible.

In general, adenovirus gene transfer systems are based upon recombinant, engineered adenovirus that is rendered replication-incompetent by deletion of a portion of its genome, such as E1, and yet still retains its competency for infection. Relatively large foreign proteins can be expressed when additional deletions are made in the adenovirus genome. For example, adenoviruses deleted in both E1 and E3 regions are capable of carrying up to 10 Kb of foreign DNA and can be grown to high titers in 293. Surprisingly, persistent expression of transgenes following adenoviral infection is possible. Use of the adenovirus gene transfer system can be more useful for the delivery of *Math1* to cells in nascent or damaged cartilage in joints. In particular, the *Math1* adenovirus can be used to deliver *Math1*, and confer *Math1* gene expression in, non-ossified joint cartilage that has been damaged as a consequence of osteoarthritis.

EXAMPLE 15

***Math1*-Adenovirus Constructs**

Recombinant virions for the controlled expression of *Math1* can be constructed to exploit the advantages of adenoviral vectors, such as high titer, broad target range, efficient transduction, and non-integration in target cells for the transformation of cells into hair cells. In a specific embodiment these constructs include a *Hath1* or any atonal-associated nucleic acid sequence. In one embodiment of the invention, a replication-defective, helper-independent adenovirus is created that expresses wild type *Math1* sequences under the control of the human cytomegalovirus promoter or the metallothionine promoter.

Control functions on expression vectors are often provided from viruses when expression is desired in mammalian cells. For example, commonly used promoters are derived from polyoma, adenovirus 2 and simian virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments can also be used provided there is included the approximately 250 bp sequence extending from the *HindIII* site toward the *BglII* site located in the viral origin of replication. Further, it is also possible, and often desirable, to use promoter or control sequences normally associated with the *Math1* gene sequence, namely the *Math1* promoter, provided such control sequences are compatible with the host cell systems or the target cell. One such target cell is located in the inner ear of a human patient in need of inner ear hair cells.

An origin of replication can be provided by construction of the vector to include an exogenous origin, such as can be derived from SV40 or other viral (*e.g.*, polyoma, adeno, VSV, BPV) source, or can be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often
5 sufficient.

EXAMPLE 16

***Atonal*-Associated Nucleic Acid Delivery using Retrovirus**

Another approach for gene delivery capitalizes on the natural ability of viruses
10 to enter cells, bringing their own genetic material with them. Retroviruses have promise as gene delivery vectors due to their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and because they are easily packaged in special cell-lines. Retroviruses can be particularly useful for the delivery of *Math1* into inner ear hair cells
15 that have reduced expression of *Math1*, or that are in need of over-expression of *Math1*. In another embodiment these constructs include a *Hath1* or any *atonal*-associated nucleic acid sequence.

EXAMPLE 17

***Math1* Retroviral Constructs**

20 The *Math1* open reading frame (ORF) was excised from pBluescript by an *EcoR* I-*Xba*I digest. The fragment was gel purified, and blunt ended using Klenow DNA polymerase. The retroviral vector pLNCX (purchased from CLONTECH) was linearized

with *Hpa*I, and ligated with the *Math1* ORF fragment. The ligation was transformed into transformation competent *E. coli* cells. The resulting antibiotic resistant colonies were assayed for the presence of the correct construct.

The cloning, reproduction and propagation retroviral expression vectors is well known to those of skill in the art. One example of a retroviral gene transfer and expression system that has been used to express *Math1* is the CLONTECH pLNCX, pLXSN and LAPSN expression vectors. For propagation of these vectors PT67 and EcoPack packaging cell lines can be used. For more information on mammalian cell culture, the following general references can be used: *Culture of Animal Cells*, Third Edition, edition by R. I. Freshney (Wiley-Liss, 1993); and *Current Protocols in Molecular Biology*, ed. By F. M. Ausubel, *et al.*, (Greene Publishing Associates and Wiley & Sons, 1994), relevant portions incorporated herein by reference.

In another embodiment constructs can be generated which include a *Hath1* or any *atonal*-associated nucleic acid sequence.

EXAMPLE 18

Maintenance of Packaging Cell Lines

The maintenance of packaging cell lines, such as the 293 and PT67 packaging cell lines, is described briefly. A vial of frozen cells is transferred from liquid N₂ to a 37°C water bath until just thawed. In order avoid osmotic shock to the cells, and to maximize cell survival, 1 ml of (Dulbecco's Modified Eagle Medium) DMEM is added to the tube and the mixture is transferred to a 15-ml tube. Another 5 ml of DMEM is added and the cells are mixed. After repeating these steps the final volume in the tube should be about

12 ml. Next, the cells are centrifuged at 500 x g for 10 min. Finally, the supernatant is removed and the cells are resuspended in maintenance media as described in the next step. Generally, the cells are maintained in DMEM (high glucose: 4.5 g/L) containing 10% Fetal Bovine Serum (FBS), and 4 mM L-glutamine. If desired or necessary, 100 U/ml penicillin/100 µg/ml streptomycin can be added. It is recommended that are plated at 3-5 x 10⁵ per 100-mm plate and split every 2 to 3 days, when they reach 70-80% confluency (confluence is 3-4 x 10⁶ per 100-mm plate). The PT67 cell line, for example, has a very short doubling time (<16h) and should be split before they become confluent. The doubling time for EcoPack-293 cells is 24-36 h.

Cells are split by removing the medium and washing the cells once with PBS. After treatment with 1-2 ml of trypsin-EDTA solution for 0.5-1 min, 5 to 10 ml of media and serum is added to stop trypsinization. The cells are dispersed gently, but thoroughly, by pipetting and are resuspended. Alternatively, a predetermined portion of the cells is replated in a 100-mm plate in 10 ml of medium, followed by rotation or shaking of the plate to distribute the cells evenly. A ratio of up to 1:20 for the PT67 or EcoPack-293 cells is common.

Generally, the percentage of PT67 or EcoPack-293 cells capable of packaging retroviral vectors decreases slowly with continued passage of the cell line. Therefore, packaging cells should be reselected after 2 months of growth in culture. Alternatively, new high-titer cells can be purchased from, e.g., CLONTECH, or low passage number stocks can be frozen, stored and thawed to increase the viral yield.

EXAMPLE 19

Methods Utilizing a Retroviral Vector

The following protocol is used to transfect the retroviral vector for virus production, infection of target cells, and selection of stable clones. Other methods and
5 vectors can also be used with the present invention to express *Math1*, such as those described in *Retroviruses*, ed. by J. M. Coffin & H. E. Varmus (1996, Cold Spring Harbor Laboratory Press, NY) and *Current Protocols in Molecular Biology*, ed. by F. M. Ausubel *et al.* (1994, Greene Publishing Associates and Wiley & Sons), incorporated
10 *atonal*-associated nucleic acid sequence.

Briefly, the transfection of the retroviral vector into PT67 cells was as follows. *Math1* was cloned into pLNx as described hereinabove. The packaging cells were plated to a density of $5-7 \times 10^5$ cells per 100-mm plate 12-24 hours before transfection. 1-2 hours before transfection, the medium replace with fresh medium. 25 μ M chloroquine
15 can be added just prior to transfection. Chloroquine increases transfection efficiency 2-3 fold. A 25 mM stock solution of chloroquine can be made in distilled water and filter sterilized.

To each 100-mm plate 10-15 μ g of plasmid DNA using the desired method is transfected using, e.g., standard calcium-phosphate procedures (CalPhos Mammalian
20 Transfection Kit, #K2050-1). The final volume of transfection mixture should not exceed 1 ml. The transfection solution is added to the medium and the plate is rotated to ensure even distribution. About 8 hours after transfection, a glycerol shock treatment can be performed to increase the uptake of DNA. After 10 to 24 hours post-transfection the

medium was removed and the cells were washed twice with PBS, before adding 5 ml DMEM containing 10% FBS. The culture was incubated for an additional 12-48 hours to allow increase in virus titer. The virus titer reaches a maximum ~ 48 hours post-transfection and is generally at least 30% of maximum between 24 and 72 hours post-transfection.

Alternatively, a stable virus-producing cell lines can also be selected. To obtain stable virus-producing cell lines, the transfected packaging cells are plated in a selection medium 2-3 days post-transfection. For G418 selection of neomycin resistance, the cells are selected in the presence of G418 (0.5 mg/ml “active”) for one week. Vectors carrying other selectable markers such as Puro, Bleo, or Hyg, can be used to obtain stable virus producing cell populations as well. Cell populations producing virions that produce titers of 10^5 - 10^6 recombinant virus particles per ml are common. Generally, 10^5 - 10^6 recombinant virus particles per ml is suitable for most purposes. For some studies, higher titer clones can be required. In this case, after antibiotic selection, individual clones are selected using, e.g., clone cylinders or limiting dilution, prior to propagation.

Viral titer can be determined in a variety of ways, one such method is described hereinbelow. The viral titer produced by transiently transfected or stable virus-producing packaging cell lines is determined as follows, NIH/3T3 cells are plated one day prior to beginning the titer procedure. Cells are plated in 6-well plates at a density of 5×10^4 - 1×10^5 cells per well and 4 ml of media are added per well. Virus-containing medium is collected from packaging cells, and polybrene is added to a final concentration of 4 μ g/ml. The medium is filter-sterilized through a 0.45- μ m filter. Polybrene is a polycation that reduces the charge repulsion between the virus and the cellular

membrane. The filter should be cellulose acetate or polysulfonic (low protein binding) but not nitrocellulose. Nitrocellulose binds proteins in the retroviral membrane, and consequently destroys the virus. Serial dilutions are prepared as follows: six 10-fold serial dilutions are usually sufficient. To dilute the virus use fresh medium containing 4 μ g/ml of polybrene. Next, NIH/3T3 target cells are infected by adding virus-containing medium to the wells. After 48 hours, the NIH/3T3 cells are stained. The titer of virus corresponds to the number of colonies present at the highest dilution that contains colonies, multiplied by the dilution factor. For example, the presence of four colonies in the 10^5 dilution would represent a viral titer of 4×10^5 .

For the infection of cells, the following procedure was followed. The target cells were plated 12-18 hours before infection at a cell density of $3-5 \times 10^5$ per 100-mm plate. For the infection of cells that can be used for a biological assay, control cells can be treated with an insert-free virus produced under identical conditions. Half-maximal infection generally occurs after 5-6 hours of exposure of cells to virus, with maximal infection occurring after approximately 24 hours of exposure. The actual reverse transcription and integration of the retrovirus takes place within 24-36 hours of infection, depending on cell growth kinetics. Expression can be observed at 24 hours, and reaches a maximum at approximately 48 hours. Alternatively, infections can be conducted sequentially, about 12 hours apart. Sequential infection generally increases the efficiency of infection and also increases viral copy number. A minimum of 12 hours between each infection is recommended in order to ensure that cellular receptors will be unoccupied by viral envelope.

EXAMPLE 20

Screening Assays

Finally, the present invention also provides candidate substance screening methods that are based upon whole cell assays, *in vivo* analysis and transformed or immortal cell lines in which a reporter gene is employed to confer on its recombinant hosts a readily detectable phenotype that emerges only under conditions where *Math1* would be expressed, is under-expressed or is over-expressed. Generally, reporter genes encode a polypeptide not otherwise produced by the host cell that is detectable by analysis, e.g., by chromogenic, fluorometric, radioisotopic or spectrophotometric analysis. In the present invention the *Math1* gene has been replaced with β -galactosidase in a mouse.

An example of a screening assay of the present invention is presented herein. *Math1* expressing cells are grown in microtiter wells, followed by addition of serial molar proportions of the small molecule candidate to a series of wells, and determination of the signal level after an incubation period that is sufficient to demonstrate, e.g., calretinin expression in controls incubated solely with the vehicle used to resuspend or dissolve the compound. The wells containing varying proportions of candidate are then evaluated for signal activation. Candidates that demonstrate dose related enhancement of reporter gene transcription or expression are then selected for further evaluation as clinical therapeutic agents. The stimulation of transcription can be observed in the absence of expressed *Math1*, in which case the candidate compound might be a positive stimulator of hair cell differentiation. Alternatively, the candidate compound might only give a stimulation in the presence of low levels of *Math1*, which would suggest that it functions to stabilize

the formation of *Math1* dimers or the interaction of *Math1* with one or more transcriptional factors. Candidate compounds of either class might be useful therapeutic agents that would stimulate production of inner ear hair cells and thereby address the need of patients with hearing loss or balance control impairments.

5

EXAMPLE 21

Transfection of Cells with *Math1* Retroviral Vectors

The present invention provides recombinant host cells transformed or transfected with a polynucleotide that encodes *Math1*, as well as transgenic cells derived from those
10 transformed or transfected cells. In another embodiment these constructs include a *Hath1* or any *atonal*-associated nucleic acid sequence. Preferably, a recombinant host cell of the present invention is transfected with a polynucleotide containing a functional *Math1* nucleic acid sequence or a chimeric *Math1* gene. Methods of transforming or transfecting cells with exogenous polynucleotides, such as DNA molecules, are well
15 known in the art and include techniques such as calcium-phosphate- or DEAE-dextran-mediated transfection, protoplast fusion, electroporation, liposome mediated transfection, direct microinjection and adenovirus infection.

Math1 expression using recombinant constructs can be used to target the delivery of *Math1* to cells in need thereof. Different promoter-vector combinations can be chosen
20 by a person skilled in these arts to drive *Math1* expression in different cell types. In some cases, the desired outcome can not be protein, but RNA, and recombinant vectors would include those with inserts present in either forward or reverse orientations. In addition, some vectors, for instance retroviruses or artificial recombination systems, can be

designed to incorporate sequences within a cellular or viral genome in order to achieve constitutive or inducible expression of protein or RNA.

Many of the vectors and hosts are available commercially and have specific features that facilitate expression or subsequent purification. For instance DNA sequences to be expressed as proteins often appear as fusion with unrelated sequences that encode polyhistidine tags, or HA, FLAG, myc and other epitope tags for immunochemical purification and detection, or phosphorylation sites, or protease recognition sites, or additional protein domains such as glutathione S-transferase (GST), maltose binding protein (MBP) (New England Biolabs), and so forth that facilitate purification. Vectors can also be designed that contain elements for polyadenylation, splicing, and termination, such that incorporation of naturally occurring genomic DNA sequences that contain introns and exons can be produced and processed, or such that unrelated introns and other regulatory signals require RNA processing prior to production of mature, translatable RNAs. Proteins produced in the systems described above are subject to a variety of post-translational modifications, such as glycosylation, phosphorylation, nonspecific or specific proteolysis or processing.

EXAMPLE 22

Delivery of Math1 as an Amino Acid Sequence

A peptide (11 amino acids) derived from HIV has been recently described that when fused to full length proteins and injected into mice allow a rapid dispersal to the nucleus of all cells of the body (Schwarze et al., 1999). Schwarze et al. made fusion proteins to Tat ranging in size from 15 to 120 kDa. They documented a rapid uptake of

the fusion proteins to the nuclei of cells throughout the animal, and the functional activity of said proteins was retained.

In an embodiment of the present invention there are constructs containing the *Tat* or *Tat-HA* nucleic acid sequence operatively linked to a *Math1* nucleic acid sequence.

5 In another embodiment these constructs include a *Hath1* or any atonal-associated nucleic acid sequence. The vectors are expressed in bacterial cultures and the fusion protein is purified. This purified Tat-Math1 protein or Tat-Hath1 protein is injected into animal to determine the efficiency of the Tat delivery system into the inner ear, skin, cerebellum, brain stem, spinal cord and joints. Analysis is carried out to determine the potential of
10 the Tat-Math1/Tat-Hath1 protein in hair cell and neuronal regeneration. This is a viable therapeutic approach either in its own right or in association with other methods or genes.

It should be understood that the methods to screen for compounds which affect *Math1* expression disclosed herein are useful notwithstanding that effective candidates can not be found, since it is of practical utility to know what upstream effector is
15 necessary for *Math1* transcription.

REFERENCES

20 All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

PUBLICATIONS

- Akazawa, C., Ishibashi, M., Shimizu, C., Nakanishi, S., and Kageyama, R. (1995). A mammalian helix-loop-helix factor structurally related to the product of *Drosophila* proneural gene *atonal* is a positive transcriptional regulator expressed in the developing nervous system. *J Biol Chem* 270, 8730-8.
- 5
- Alder, J., Cho, N., and Hatten, M. (1996). Embryonic precursor cells from the rhombic lip are specified to a cerebellar granule neuron identity. *Neuron* 17, 389-399.
- Altman, J., and Bayer, S. A. (1996). Development of the Cerebellar System: In Relation to its Evolution, Sturcture, and Functions. Boca Raton, Florida: CRC Press.
- 10
- Anderson, D. J. (1995). Neural development. Spinning skin into neurons. *Curr Biol* 5, 1235-8.
- Bartholomä, A., and Nave, K. A. (1994). NEX-1: a novel brain-specific helix-loop-helix protein with autoregulation and sustained expression in mature cortical neurons. *Mech Dev* 48, 217-28.
- 15
- Ben-Arie, N., Hassan, B.A., Birmingham, N.A., Malicki, D.M., Armstrong, D., Matzuk, M., Bellen, H.J., and Zoghbi, H.Y. (2000). Functional conservation of *atonal* and *Math1* in the CNS and PNS. *Development* 127: 1039-1048.
- 20

Ben-Arie, N., Bellen, H. J., Armstrong, D. L., McCall, A. E., Gordadze, P. R., Guo, Q., Matzuk, M. M., and Zoghbi, H. Y. (1997). *Math1* is essential for genesis of cerebellar granule neurons. *Nature* 390, 169-172.

5 Ben-Arie, N., McCall, A. E., Berkman, S., Eichele, G., Bellen, H. J., and Zoghbi, H. Y. (1996). Evolutionary conservation of sequence and expression of the bHLH protein Atonal suggests a conserved role in neurogenesis. *Human Molecular Genetics* 5, 1207-1216.

10 Bermingham, N. A., Hassan, B. A., Price, S. D., Vollrath, M. A., Ben-Arie, N., Eatock, R. A., Bellen, H. J., Lysakowski, A., and Zoghbi, H. Y. (1999). *Math1*: An essential gene for the generation of inner ear hair cells. *Science* 284, 1837-41.

15 Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrughe, B. (1999). Sox9 is required for cartilage formation. *Nat Genet* 22, 85-9.

Bonnerot, C., and Nicolas, J. F. (1993). Application of LacZ gene fusions to postimplantation development. *Methods Enzymol* 225, 451-69.

20 Boyan, G. S. (1993). Another look at insect audition: the tympanic receptors as an evolutionary specialization of the chordotonal system. *J Insect Physiol* 39, 187-200.

Brand, A. H., and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* 118, 401-15.

Brown, N. L., Kanekar, S., Vetter, M. L., Tucker, P. K., Gemza, D. L., and Glaser, T.

5 (1998). Math5 encodes a murine basic helix-loop-helix transcription factor expressed during early stages of retinal neurogenesis. *Development* 125, 4821-4833.

Buckwalter, J. A., and Mankin, H. J. (1998). Articular cartilage: tissue design and chondrocyte-matrix interactions. *Instr Course Lect* 47, 477-86.

10

Chien, C. T., Hsiao, C. D., Jan, L. Y., and Jan, Y. N. (1996). Neuronal type information encoded in the basic-helix-loop-helix domain of proneural genes. *Proc Natl Acad Sci U S A* 93, 13239-44.

15 Davis, R. L., Cheng, P. F., Lassar, A. B., and Weintraub, H. (1990). The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. *Cell* 60, 733-46.

Dreller, C., and Kirschner, W. H. (1993). Hearing in honeybees: localization of the
20 auditory sense organ. *J. Comp Physio A* 173, 275-279.

Eberl, D. F. (1999). Feeling the vibes: chordotonal mechanisms in insect hearing. *Curr Opin Neurobiol* 9, 389-393.

Ferguson, B. M., Brockdorff, N., Formstone, E., Ngyuen, T., Kronmiller, J. E., and Zonana, J. (1997). Cloning of Tabby, the murine homolog of the human EDA gene: evidence for a membrane-associated protein with a short collagenous domain. *Hum Mol Genet* 6, 1589-94.

5

Fode, C., Gradwohl, G., Morin, X., Dierich, A., LeMeur, M., Goridis, C., and Guillemot, F. (1998). The bHLH protein NEUROGENIN 2 is a determination factor for epibranchial placode-derived sensory neurons. *Neuron* 20, 483-94.

10 Friedrich, G., and Soriano, P. (1991). Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. *Genes Dev* 5, 1513-23.

Ghyssen, A., and Dambly-Chaudiere, C. (1989). Genesis of the *Drosophila* peripheral nervous system. *Trends Genet* 5, 251-5.

15

Gruneberg, H. (1971). The tabby syndrome in the mouse. *Proc R Soc Lond B Biol Sci* 179, 139-156.

Guillemot, F. (1995). Analysis of the role of basic-helix-loop-helix transcription factors
20 in the development of neural lineages in the mouse. *Biol Cell* 84, 227-241.

Hatten, M. E., and Heintz, N. (1995). Mechanisms of neural patterning and specification in the developing cerebellum. *Ann Rev Neurosci* 18, 385-408.

Helms, A. W., and Johnson, J. E. (1998). Progenitors of dorsal commissural interneurons are defined by MATH1 expression. *Development* 125, 919-28.

- Horton, W. A., Machado, M. A., Ellard, J., Campbell, D., Putnam, E. A., Aulthouse, A. L., Sun, X., and Sandell, L. J. (1993). An experimental model of human chondrocyte differentiation. *Prog Clin Biol Res* 383B, 533-40.

Jarman, A. P., and Ahmed, I. (1998). The specificity of proneural genes in determining *Drosophila* sense organ identity. *Mech Dev* 76, 117-25.

10

Jarman, A. P., Grau, Y., Jan, L. Y., and Jan, Y. N. (1993). *atonal* is a proneural gene that directs chordotonal organ formation in the *Drosophila* peripheral nervous system. *Cell* 73, 1307-21.

- 15 Kania, A., Salzberg, A., Bhat, M., D'Evelyn, D., He, Y., Kiss, I., and Bellen, H. J. (1995). P-element mutations affecting embryonic peripheral nervous system development in *Drosophila melanogaster*. *Genetics* 139, 1663-1678.

Karsenty, G. (1998). Genetics of skeletogenesis. *Dev Genet* 22, 301-13.

20

Lee, J. E. (1997). Basic helix-loop-helix genes in neural development. *Curr. Opin. Neurobiol* 7, 13-20.

Lee, K. J., Mendelsohn, M., and Jessell, T. M. (1998). Neuronal patterning by BMPs: a requirement for GDF7 in the generation of a discrete class of commissural interneurons in the mouse spinal cord. *Genes Dev* 12, 3394-407.

- 5 Liu, X. Y., Dangel, A. W., Kelley, R. I., Zhao, W., Denny, P., Botcherby, M., Cattanaach, B., Peters, J., Hunsicker, P. R., Mallon, A. M., Strivens, M. A., Bate, R., Miller, W., Rhodes, M., Brown, S. D., and Herman, G. E. (1999). The gene mutated in bare patches and striated mice encodes a novel 3beta-hydroxysteroid dehydrogenase. *Nat Genet* 22, 182-7.

10

Ma, Q., Chen, Z., del Barco Barrantes, I., de la Pompa, J. L., and Anderson, D. J. (1998). neurogenin1 is essential for the determination of neuronal precursors for proximal cranial sensory ganglia. *Neuron* 20, 469-82.

- 15 McCormick, M. B., Tamimi, R. M., Snider, L., Asakura, A., Bergstrom, D., and Tapscott, S. J. (1996). NeuroD2 and neuroD3: distinct expression patterns and transcriptional activation potentials within the neuroD gene family. *Mol Cell Biol* 16, 5792-800.

McIver, S. B. (1985). Mechanoreception. In *Comprehensive Insect Physiology, Biochemistry, and Pharmacology* (G. A. Kerkut and L. I. Gilbert, Eds.), pp. 71-132. Oxford: Pergamon Press.

Moulins, M. (1976). Ultrastructure of chordotonal organs. In *Structure and Function of Proprioceptors in the Invertebrates* (P. J. Mill, Ed.), pp. 387-426. London: Chapman and Hall.

- 5 Munger, B. L. (1991). The Biology of Merkel Cells. In *Physiology, Biochemistry, and Molecular Biology of the Skin*, second edition (L. A. Goldsmith, Ed.), pp. 836-856. Oxford, UK: Oxford University Press.

- 10 Pinkus, F. (1905). Über Hautsinnesorgane neben dem menschlichen Haar (Haarscheiben) und ihre vergleichend-anatomische Bedeutung. *Arch mikr Anat* 65, 121-179.

Poole, C. A. (1997). Articular cartilage chondrons: form, function and failure. *J Anat* 191, 1-13.

- 15 Rodriguez, I., Hernandez, R., Modolell, J., and Ruiz-Gomez, M. (1990). Competence to develop sensory organs is temporally and spatially regulated in *Drosophila* epidermal primordia. *Embo J* 9, 3583-92.

- 20 Sambrook, Fritsch, Maniatis, In: *Molecular Cloning: A Laboratory Manual*, Vol. 1, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Ch. 7, 7.19-17.29, 1989.

Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. (1999). In vivo protein transduction: delivery of a biologically active protein in the mouse. *Science* 285, 1569-72.

Shimizu, C., Akazawa, C., Nakanishi, S., and Kageyama, R. (1995). MATH-2, a
5 mammalian helix-loop-helix factor structurally related to the product of *Drosophila* proneural gene *atonal*, is specifically expressed in the nervous system. *Eur J Biochem* 229, 239-48.

Sun, Y., Jan, L. Y., and Jan, Y. N. (1998). Transcriptional regulation of *atonal* during
10 development of the *Drosophila* peripheral nervous system. *Development* 125, 3731-40.

Takebayashi, K., Takahashi, S., Yokota, C., Tsuda, H., Nakanishi, S., Asashima, M., and
Kageyama, R. (1997). Conversion of ectoderm into a neural fate by *ATH-3*, a vertebrate
basic helix-loop-helix gene homologous to *Drosophila* proneural gene *atonal*. *Embo J*
15 16, 384-95.

Tautz, D., and Pfeifle, C. (1989). A nonradioactive in situ hybridization method for the
localization of specific RNAs in *Drosophila* embryos reveals translation control of the
segmentation gene *hunchback*. *Chromosoma* 98, 81-85.

20 Vaessin, H., Caudy, M., Bier, E., Jan, L. Y., and Jan, Y. N. (1990). Role of
helix-loop-helix proteins in *Drosophila* neurogenesis. *Cold Spring Harb Symp Quant*
Biol 55, 239-45.

van Staaden, M. J., and Römer, H. (1998). Evolutionary transition from stretch to hearing organs in ancient grasshoppers. *Nature* 384, 773-776.

5 Vielkind, U., Sebzda, M. K., Gibson, I. R., and Hardy, M. H. (1995). Dynamics of Merkel cell patterns in developing hair follicles in the dorsal skin of mice, demonstrated by a monoclonal antibody to mouse keratin 18. *Acta Anat* 152, 93-109.

10 Yamakado, M., and Yohro, T. (1979). Subdivision of mouse vibrissae on an embryological basis, with descriptions of variations in the number and arrangement of sinus hairs and cortical barrels in BALB/c (nu/+; nude, nu/nu) and hairless (hr/hr) strains. *Am J Anat* 155, 153-173.

15 Zhao, C., and Emmons, S. W. (1995). A transcription factor controlling development of peripheral sense organs in *C. elegans*. *Nature* 373, 74-78.

PATENTS

U.S. Patent No. 5,840,873, issued Nov. 24, 1998

U.S. Patent No. 5,843, 640, issued Dec. 1, 1998

U.S. Patent No. 5,843,650, issued Dec. 1. 1998

20 U.S. Patent No. 5,843,651, issued Dec. 1, 1998

U.S. Patent No. 5,843,663, issued Dec. 1, 1998

U.S. Patent No. 5,846,708, issued Dec. 8, 1998

U.S. Patent No. 5,846,709, issued Dec. 8, 1998

U.S. Patent No. 5,846,717, issued Dec. 8, 1998

U.S. Patent No. 5,846,726, issued Dec. 8, 1998

U.S. Patent No. 5,846,729, issued Dec. 8, 1998

U.S. Patent No. 5,846,783, issued Dec. 8, 1998

5 U.S. Patent No. 5,849,481, issued Dec. 15, 1998

U.S. Patent No. 5,849,483, issued Dec. 15, 1998

U.S. Patent No. 5,849,486, issued Dec. 15, 1998

U.S. Patent No. 5,849,487, issued Dec. 15, 1998

U.S. Patent No. 5,849,497, issued Dec. 15, 1998

10 U.S. Patent No. 5,849,546, issued Dec. 15, 1998

U.S. Patent No. 5,849,547, issued Dec. 15, 1998

U.S. Patent No. 5,851,770, issued Dec. 22, 1998

U.S. Patent No. 5,851,772, issued Dec. 22, 1988

U.S. Patent No. 5,853,990, issued Dec. 29, 1998

15 U.S. Patent No. 5,853,993, issued Dec. 29, 1998

U.S. Patent No. 5,853,992, issued Dec. 29, 1998

U.S. Patent No. 5,856,092, issued Jan. 5, 1999

U.S. Patent No. 5,858,652, issued Jan. 12, 1999

U.S. Patent No. 5,861,244, issued Jan. 19, 1999

20 U.S. Patent No. 5,863,732, issued Jan. 26, 1999

U.S. Patent No. 5,863,753, issued Jan. 26, 1999

U.S. Patent No. 5,866,331, issued Feb. 2, 1999

U.S. Patent No. 5,866,336, issued Feb. 2, 1999

- U.S. Patent No. 5,866,337, issued Feb. 2, 1999
- U.S. Patent No. 5,900,481, issued May 4, 1999
- U.S. Patent No. 5,905,024, issued May 18, 1999
- U.S. Patent No. 5,910,407, issued June 8, 1999
- 5 U.S. Patent No. 5,912,124, issued June 15, 1999
- U.S. Patent No. 5,912,145, issued June 15, 1999
- U.S. Patent No. 5,912,148, issued June 15, 1999
- U.S. Patent No. 5,916,776, issued June 29, 1999
- U.S. Patent No. 5,916,779, issued June 29, 1999
- 10 U.S. Patent No. 5,919,626, issued July 6, 1999
- U.S. Patent No. 5,919,630, issued July 6, 1999
- U.S. Patent No. 5,922, 574, issued July 13, 1999
- U.S. Patent No. 5,925,517, issued July 20, 1999
- U.S. Patent No. 5,925,525, issued Jul. 20, 1999
- 15 U.S. Patent No. 5,928,862, issued July 27, 1999
- U.S. Patent No. 5,928,869, issued July 27, 1999
- U.S. Patent No. 5,928,870, issued, Jul. 27, 1999
- U.S. Patent No. 5,928,905, issued July 27, 1999
- U.S. Patent No. 5,928,906, issued July 27, 1999
- 20 U.S. Patent No. 5,929,227, issued July 27, 1999
- U.S. Patent No. 5,932,413, issued Aug. 3, 1999
- U.S. Patent No. 5,932,451, issued Aug. 3, 1999
- U.S. Patent No. 5,935,791, issued Aug. 10, 1999

U.S. Patent No. 5,935,825, issued Aug. 10, 1999

U.S. Patent No. 5,939,291, issued Aug. 17, 1999

U.S. Patent No. 5,942,391, issued Aug. 24, 1999

European Application No. 320 308

5 European Application No. 329 822

GB Application No. 2 202 328

PCT Application No. PCT/US87/00880

PCT Application No. PCT/US89/01025

PCT Application WO 88/10315

10 PCT Application WO 89/06700

PCT Application WO 90/07641

One skilled in the art readily appreciates that the present invention is well adapted
15 to carry out the objectives and obtain the ends and advantages mentioned as well as those
inherent therein. Sequences, mutations, complexes, methods, treatments, pharmaceutical
compositions, procedures and techniques described herein are presently representative
of the preferred embodiments and are intended to be exemplary and are not intended as
limitations of the scope. Changes therein and other uses will occur to those skilled in the
20 art which are encompassed within the spirit of the invention or defined by the scope of
the pending claims.

What is claimed is:

1. An animal having a heterologous nucleic acid sequence replacing an allele of an *atonal*-associated nucleic acid sequence under conditions wherein said heterologous sequence inactivates said allele.
2. The animal of claim 1 wherein said heterologous nucleic acid sequence is expressed under the control of an *atonal*-associated regulatory sequence.
3. The animal of claim 1 wherein both *atonal*-associated alleles are replaced.
4. The animal of claim 3 wherein said heterologous nucleic acid sequences are nonidentical.
5. The animal of claim 3 wherein said animal has a detectable condition.
6. The animal of claim 5 wherein said detectable condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis and abnormal proliferation of cells.
7. The animal of claim 1 wherein said heterologous nucleic acid sequence is a reporter sequence.
8. The animal of claim 1, wherein said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under the control of regulatable promoter sequence.
9. The animal of claim 1, wherein said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under the control of a tissue-specific promoter sequence.

10. The animal of claim 1 wherein said animal is selected from the group consisting of a mouse, *Drosophila*, zebrafish, frog, rat, hamster and guinea pig.
11. A method for screening for a compound in an animal wherein said compound affects expression of an *atonal*-associated nucleic acid sequence comprising:
- 5 delivering said compound to said animal, wherein said animal has at least one allele of an *atonal*-associated nucleic acid sequence inactivated by insertion of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under control of an *atonal*-associated regulatory sequence; and
- 10 monitoring for a change in said expression of said *atonal*-associated nucleic acid sequence.
12. The method of claim 11 wherein said compound affects expression of an *atonal*-associated nucleic acid sequence.
13. The method of claim 11 wherein said compound affects a detectable condition in
- 15 an animal.
14. The method of claim 11, wherein said heterologous nucleic acid sequence is a reporter sequence.
15. The method of claim 11, wherein said compound affects said detectable condition.
- 20 16. A method for screening for a compound in an animal, wherein said compound affects a detectable condition in said animal, comprising:
- delivering said compound to said animal wherein at least one allele of an *atonal*-associated nucleic acid sequence in said animal is inactivated by insertion

of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under the control of an *atonal*-associated regulatory sequence, and monitoring said animal for a change in the detectable condition.

17. The method of claim 16, wherein said delivery of said compound affects expression of said heterologous nucleic acid sequence.

18. The method of claim 16 wherein said compound affects said detectable condition.

19. The method of claim 16 wherein said compound affects expression of said heterologous nucleic acid sequence.

20. A method of treating an animal with a deficiency in cerebellar granule neurons or their precursors comprising delivery of a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.

21. The method of claim 20, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.

22. The method of claim 20, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.

23. The method of claim 20, wherein said amino acid sequence or nucleic acid sequence is delivered by a delivery vehicle.

24. The method of claim 23 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof.

25. The method of claim 23, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
26. The method of claim 23, wherein said delivery vehicle is a cell.
27. The method of claim 20, wherein said cell contains an alteration in an *atonal*-associated amino acid sequence.
28. The method of claim 20, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
29. The method of claim 20, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
30. A method of promoting mechanoreceptive cell growth in an animal, comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
31. The method of claim 30, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
32. The method of claim 30, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
33. The method of claim 30, wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
34. The method of claim 33 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral

vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof.

35. The method of claim 33, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.

5 36. The method of claim 33, wherein said delivery vehicle is a cell.

37. The method of claim 30, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.

38. The method of claim 30, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).

39. The method of claim 30, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).

40. A method of generating hair cells comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.

41. The method of claim 40, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.

42. The method of claim 40, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.

43. The method of claim 40 wherein said delivery comprises injecting into an inner ear a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence.

44. The method of claim 40, wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
45. The method of claim 44 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a liposome, a peptide, a nucleic acid, a lipid, a carbohydrate and a combination thereof.
46. The method of claim 44, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
47. The method of claim 44, wherein said delivery vehicle is a cell.
48. The method of claim 40, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.
49. The method of claim 40, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
50. The method of claim 40, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
51. A method of treating an animal for hearing impairment, comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
52. The method of claim 51, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.

53. The method of claim 51, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
54. The method of claim 51 wherein said delivery comprises injecting into an inner ear a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence.
55. The method of claim 51, wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
56. The method of claim 55 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof of said vectors.
57. The method of claim 55, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
58. The method of claim 55, wherein said delivery vehicle is a cell.
59. The method of claim 51, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.
60. The method of claim 51, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
61. The method of claim 51, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).

62. A method of treating an animal for an imbalance disorder, comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
63. The method of claim 62 wherein said delivery comprises injecting into an inner ear a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence.
64. The method of claim 62, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
65. The method of claim 62, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
66. The method of claim 62, wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
67. The method of claim 66 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof of said vectors.
68. The method of claim 66, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
69. The method of claim 66, wherein said delivery vehicle is a cell.
70. The method of claim 62, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.

71. The method of claim 62, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
72. The method of claim 62, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
73. A method of treating an animal for a joint disease comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
74. The method of claim 73, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
75. The method of claim 73, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
76. The method of claim 73 wherein said delivery comprises injecting into said joint a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence.
77. The method of claim 73 wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
78. The method of claim 77 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a liposome, a nucleic acid sequence, a peptide, a lipid, a carbohydrate and a combination thereof.

79. The method of claim 77, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
80. The method of claim 77, wherein said delivery vehicle is a cell.
81. The method of claim 73, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.
- 5 82. The method of claim 73, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
83. The method of claim 73, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
- 10 84. The method of claim 73 wherein said joint disease is osteoarthritis.
85. A method of treating an animal for an abnormal proliferation of cells comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
- 15 86. The method of claim 85, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
87. The method of claim 85, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
- 20 88. The method of claim 85 wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
89. The method of claim 88 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral

vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof.

90. The method of claim 88, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
- 5 91. The method of claim 88, wherein said delivery vehicle is a cell.
92. The method of claim 85, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.
93. The method of claim 85, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
- 10 94. The method of claim 85, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
95. The method of claim 85, wherein said cell is a cancer cell.
- 15 96. A method of treating an animal for an abnormal proliferation of cells comprising altering *atonal*-associated nucleic acid sequence or amino acid sequence levels in a cell.
97. The method of claim 96, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
- 20 98. The method of claim 96, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
99. The method of claim 96 wherein said *atonal*-associated nucleic acid sequence or amino acid sequence contains an alteration.

100. The method of claim 96, wherein said cell is a cancer cell.
101. A method of treating an animal for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
102. The method of claim 101, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
103. The method of claim 101, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
104. The method of claim 101 wherein said amino acid sequence or nucleic acid sequence is administered by a delivery vehicle.
105. The method of claim 104 wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a liposome, a protein, a lipid, a carbohydrate and a combination thereof of said vectors.
106. The method of claim 104, wherein said delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.
107. The method of claim 104, wherein said delivery vehicle is a cell.
108. The method of claim 101, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.
109. The method of claim 101, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).

110. The method of claim 101, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
111. The method of claim 101, wherein said cell is a cancer cell.
- 5 112. A composition comprising an *atonal*-associated amino acid sequence or nucleic acid sequence in combination with a delivery vehicle, wherein said delivery vehicle results in delivery of a therapeutically effective amount of *atonal*-associated nucleic acid sequence or amino acid sequence into a cell.
- 10 113. The composition of claim 112, wherein said delivery vehicle comprises a vector that expresses an *atonal*-associated nucleic acid sequence or amino acid sequence in an animal cell.
114. The composition of claim 113, wherein said vector is selected from the group consisting of a viral vector, a plasmid, a liposome, a protein, a lipid, a carbohydrate and a combination thereof of said vehicles.
- 15 115. The composition of claim 112, wherein said delivery vehicle is the receptor-binding domain of a bacterial toxin.
116. The composition of claim 112, wherein said *atonal*-associated nucleic acid sequence is operatively linked to nucleic acid sequence encoding a receptor-binding domain of a bacterial toxin.
- 20 117. The composition of claim 112 wherein said *atonal*-associated nucleic acid sequence is operatively linked to nucleic acid sequence encoding a protein transduction domain.

118. The composition of claim 112, wherein said *atonal*-associated nucleic acid sequence is *Hath1*.
119. The composition of claim 112, wherein said *atonal*-associated nucleic acid sequence is *Math1*.

ABSTRACT

Compositions and methods are disclosed for the therapeutic use of an *atonal*-
associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an
5 *atonal*-associated gene inactivation is also disclosed having at least one *atonal*-associated
nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used
to detect expression driven by an *atonal*-associated promoter sequence, wherein the
inactivation of the *atonal*-associated nucleic acid sequence prevents expression of the
atonal-associated gene.

10

15

20




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5



Figure 6B




Figure 6A






Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14